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Biologics are pharmaceuticals produced by living systems. Biosimilars, the follow-
on counterparts to biologics are unlike small-molecule generics in the fact that they are 
large and complex and may contain minor variations from the originator product. The 
presence of these variations, derived from post-translational modifications (PTMs), 
necessitates a more rigorous approval procedure than that which is implemented for 
small-molecule generics. Extensive physicochemical characterization must be 
undertaken to confirm that the biosimilar’s quality attributes closely match the originator 
in molecular and functional features. If high similarity is confirmed by these studies, the 
extent of preclinical and clinical trials may be reduced. Based on this, we performed 
extensive analytical comparability studies for filgrastim and several mAbs using various 
methods including several different liquid chromatography (LC) separations and mass 
spectrometry (MS) techniques.  
In the first study, we compared Neupogen® and its proposed biosimilar filgrastim 
in terms of structural (primary and higher order) and chemical variants (size, oxidation, 
deamidation) using tandem MS, intact MS, 2D NMR and LC separations. Both molecules 
showed identical primary structure, comparable higher order structure and low levels of 
each variant except in deamidation levels, where originator filgrastim showed higher 
levels than that of the biosimilar.  
In the second study, we combined the multi-attribute method (MAM) analysis with 
multiple orthogonal techniques to structurally compare Rituxan® and a proposed 
 xiv 
rituximab biosimilar while focus specifically on glycosylation and resulting biological 
activity. We hypothesized that different glycosylation distributions between the originator 
and biosimilar rituximab could result in different biological activities, including differences 
in binding affinity to the FcγIIIA receptor and differences in antibody dependent cell 
cytotoxicity (ADCC). We show that both mAbs had identical primary structures by tandem 
MS and similar higher order structures by ion mobility (IM) MS and hydrogen deuterium 
exchange (HX) MS. We observed similar levels of deamidation and oxidation for both 
products, but significant differences in the levels of specific glycoforms. In particular, the 
biosimilar not only had a higher level of afucosylated glycans but also showed a higher 
FcγIIIA binding affinity and higher ADCC potency, thus suggesting a possible difference 
in clinical efficacy. 
Finally, we identified initial structural differences/similarities and attempted to 
identify whether or not these differences could be amplified through the application of 
thermal stress through three originator-biosimilar pairs; rituximab, bevacizumab and 
trastuzumab. Initially, we detected highly similar secondary and tertiary structures and 
different levels of size and charge variants for each pair. After 4 weeks of incubation at 
40 ºC, we measured differences in charge variant distributions and unfolding patterns. 
Taken together, our study shows the ability to establish comparability by creating a profile 
of initial differences for multiple mAb pairs and determining how those differences change 
when subject to thermal stress.   
In conclusion, our studies provide an exemplary analytical exercise that can be 
implemented in the development of future biosimilar products.  
 
 1 
Chapter 1: Introduction 
 Key characteristics of biologic products 
Biologic product development is a growing field with a breadth of impact in cancer 
[1], and hematologic [2], autoimmune [3], and infectious diseases [4]. As of June 2017, 
approximately 2700 biologics are under development [5], fueled by their efficacy, safety, 
and the advancements in technology and regulatory pathways. [6–8] Biologic products 
are large complex molecules derived from living cells and can include therapeutic 
recombinant proteins, vaccines, or blood components. They are distinct from the relatively 
simple structure of small molecule drugs and have a more complicated manufacturing 
process. As shown in Figure 1-1, small molecules, such as acetaminophen at 151.2 da 
in size, can be thought of as a bicycle compared to the 30-150 kDa small and large 
biologics, erythropoietin and an IgG antibody, which would be considered the much more 
complicated, car or airplane. Biologics are not only more complex in structure, they 
also require a more elaborate and delicate manufacturing process than the chemical 
synthesis of small molecules, relying on the living cell system which is dynamic and highly 
sensitive to the external environment, leading to their heterogeneity and higher potential 
for immunogenicity. [9–11] For these reasons, development of biosimilars, is far more 








Biologic products are increasingly coming off patent, which has opened up the 
opportunity for biosimilar development and approvals. Notably, a biosimilar is not 
considered a generic version of a biologic since it is impossible to produce identical copies 
of biologic products. A biosimilar is a follow-on biologic which is highly similar in safety, 
purity and potency to an approved innovator biologic. [12,13] Since 2006, the European 
Medicines Agency (EMA) has led the approval of biosimilars with 54 approved products, 
and the U.S. Food and Drug Administration (FDA) has approved 23 biosimilars as of July 
2019. [14,15]  
1.2.1 Key differences between generics and biosimilars 
The development process of a biosimilar is more complicated than generic drug 
product development due to the complexity of the innovator biologic, requiring a much 
more detailed approval process than the generic drug approval. As depicted in Figure 1-
 3 
2, innovator biologic, biosimilar, and generic drug developments differ in the extent of the 
process as well as where the bulk of the analysis lies. The abbreviated generic drug 
approval process only requires proof of matching between innovator and generic 
bioequivalence and bioavailability data in healthy subjects. [16,17] The innovator biologic 
development process places most emphasis on the clinical data, whereas the biosimilar 
development process requires a more extensive analytical development and 
characterization process due to the complexities of structure and manufacturing process. 
[18,19] Biologics, unlike generics, can have different indications than their innovator 
product due to differences in mechanisms of action (MoA) across indications, number or 
complexity of binding sites, or confound risk factors within different disease populations. 
[20,21] For example, the innovator of epoetin alfa (Epogen®) was initially approved for 
cancer treatment but the biosimilar, Binocrit, was approved for anemia and chronic kidney 
failure and not cancer. [22] In contrast to generics, innovator and biosimilar products 
cannot be interchangeably dispensed in the US. [23] The FDA requires the submission 
of an additional application in order to attain interchangeability status, allowing for the 
biosimilar product to be attained by patients without the need for a new prescription. As 
of July 2019, no US biosimilar has been granted interchangeability status. [24] The EMA 
does not have a policy in place for evaluating interchangeability, relying on individual 
member states to determine whether drugs are interchangeable. [25]  
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Figure 1-2 Differences in drug development processes: innovator, biosimilar and generic. 
PK: pharmacokinetics; PD: pharmacodynamics; BA: bioavailability; BE: bioequivalence 
 
 Manufacturing process and consideration for biologic/biosimilar products 
The innovator biologic manufacturing processes is proprietary information, thus an 
exact replicate cannot be produced, resulting in alterations in the final biosimilar product. 
[26–28] The manufacturing process of biologics is depicted in Figure 1-3 and is discussed 
elsewhere. [29–33]  Each manufacturing step is extremely sensitive to changes in the 
external environment and can influence the final biologic product, even impacting batch-
to-batch variation within a strictly controlled facility. [33–35] Thus, the manufacturing 
processes and any changes made to it need to be approved by regulatory agencies, 
confirming no effect on the overall clinical efficacy or safety. [36–40] For example, 
manufacturing changes in rituximab (Rituxan®) caused a shift in basic variants and a 
higher antibody dependent cell cytotoxicity (ADCC) potency, which ultimately involves the 
mechanism of action, although it was not predicted to result in any changes in clinical 
outcome. [34]  
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1.3.1 Critical quality attributes 
Critical quality attributes (CQAs) are defined as a physical, chemical, biological, or 
microbiological property that should be within an appropriate limit, range, or distribution 
to ensure the desired product quality. [41] Establishing CQAs for biosimilar products start 
by selecting quality attributes (QAs) based on molecular structure, mechanism of action, 
safety and efficacy and defining analytical methods to test them. [42,43] Through various 
models, the risk and impact on clinical outcome (PK, PD, etc.) of each QA is assessed 
through quantitative and/or qualitative methods and criticality is assigned. In one example 
of criticality scoring, a score is assigned by multiplying two categories: impact x 
uncertainty, where a known (low uncertainty) clinical impact would rank higher than an 
unknown potential (high uncertainty) clinical impact. The drawback of using a quantitative 
method such as this is its sensitivity to changes in individual scores which can result in 
major shifts and inconsistency in criticality ranking of QAs. On the other hand, using a 
Figure 1-3 Biologics manufacturing process; (1) production of cell line, (2) cell culture, (3) 
large scale cell culture – fermentation, (4a) purification, (4b) conjugation, and (5) formulation, 
filling and packaging. Images reproduced with permission from Roche. 
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qualitative approach involving more judgement and expert opinion can be used, but is 
less substantiated or standardized.[47] Examples of CQAs based on their criticality that 
are used for the analytical biosimilarity assessment of infliximab biosimilar (Inflectra®) 
and filgrastim biosimilar (Zarxio®) are shown in Table 1-1.  
Table 1-1 Examples of CQAs for the analytical biosimilarity assessment of a mAb drug – 
infliximab and a small protein drug – filgrastim. [49,50] **Relative criticality was assigned by each 
developer based on literature and experiments 
Example 1: Infliximab biosimilar – Inflectra® Example 2: Filgrastim biosimilar - Zarxio® 
CQAs Criticality** Related to CQAs Criticality** Related to 
Primary structure High 
Efficacy, safety, 
immunogenicity 
Primary structure Very high 
Efficacy, safety, 
immunogenicity 
Protein content High Efficacy Protein content Very high Efficacy 
FcRn binding High PK Potency Very high Efficacy, safety 
Target binding to 
sTNF-α 




















Oxidized species High Efficacy 













Very low None 







Very low None 
Fc binding Low 
Immune system 
mediator 
   
 
Next, the FDA also requires a tier assignment, based on risk and potential clinical 
impact and uncertainty, of each of the specified methodologies used to analytically assess 
the CQAs. [42] An overview of the 3-tier system including examples of QAs for specific 
biologics (infliximab and filgrastim) and statistical methods is shown in Table 1-2. In tier 
1, CQAs with a high criticality that affect biological activity, PK/PD, immunogenicity, and 
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safety, require statistical equivalence tests between innovator and biosimilar. In tier 2, 
CQAs with moderate criticality that have potential impact on biological activity, PK/PD, 
immunogenicity, and safety require a quality range approach where values must fall within 
a specified number of standard deviations from a mean value, depending on the 
assessment. In tier 3, CQAs with low criticality which have no impact on biological activity, 
PK/PD, immunogenicity and safety, are assigned and assessed more comparatively, this 
is also where qualitative and techniques binary in nature are categorized. [43,44] The 
FDA has not officially determined a preferred method for CQA or criticality determination 
and has recently withdrawn a draft guidance document on “statistical approaches to 
evaluate analytical similarity” due to the complexities involved with the number of product 
lots required and the possibility of false-negative equivalence results, ultimately affecting 
the efficiency and cost of biosimilar development. [45–48] In contrast, the EMA does not 
require tier assignment for analytical assessments nor a specific subsequent statistical 
analysis method, but is also currently discussing ways to improve and define the 
analytical assessment of biosimilarity through critical quality attributes along with the FDA. 
[49]  
Examples of quality attributes of interest include amino acid sequence, disulfide 
bridges, carbohydrate attachment, molecular weight, extinction coefficient, and 
electrophoretic, liquid chromatographic, and spectroscopic patterns. [50,51] A multi-level 
comparison of biosimilars with their reference drugs must be conducted prior to approval 
in which any potential differences are detected and determined not to change 
immunogenicity, safety, or efficacy profiles outside the range of variation for the originator 
drug. Important quality attributes can be broken up into several categories: primary 
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structure, higher order structure, size, post-translational modifications, purity, and binding 
activity. 
Table 1-2 The 3-tiered approach for biosimilar statistical quality attribute evaluation. 










Critical quality attributes 
most relevant to clinical 
outcomes 
Target binding (e.g. TNF-α 
binding), protein concentration 
Target binding, potency, 
protein concentration, amino 
acid sequence 




Less critical quality 
attributes moderately 
relevant to clinical 
outcomes 
Peptide mapping, Glycosylation 
Subvisible particle, 
aggregates 
Quality range approach: 
mean ± xδ 
3 sd 
3 
Least critical quality 
attributes least relevant 








 Physicochemical assessment of biosimilarity 
1.4.1 Primary structure 
Alterations in protein amino acid sequence composition can alter the hydrogen 
bonding patterns of α-helixes and β-sheets, which can influence protein folding and 
binding with protein ligands, potentially resulting in changes to its functionality. [52] 
Hence, biosimilars must have 100 percent primary sequence similarity to the reference 
product, no variability of primary structure is permitted. [25,26] 
Currently, the most widely used method to elucidate the primary sequence is 
through reverse phase liquid chromatography (RP-LC), coupled with mass spectrometry 
(MS) based techniques. These include a variety of applications ranging from intact mass 
to peptide mapping. [53–57] As a top-down method, intact mass can be used to confirm 
the primary structure in a macroscopic manner, where data can provide rapid and precise 
profiling through matrix-assisted laser desorption/ionization (MALDI) or electrospray 
ionization (ESI) coupled to a time-of-flight (TOF), quadrupole (Q), ion trap (IT) or LTQ-
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Orbitrap. [50] Differences of intact mass measurements indicate the presence of primary 
structural variation, which may occur as a result of an altered amino acid sequence. As a 
bottom-up method, peptide mapping involves the chemical or enzymatic digestion of 
protein into its constituent peptide fragments, which are subsequently separated by LC 
and analyzed by MSn. A crucial consideration for peptide mapping is to maximize peptide 
sequence coverage, which can be achieved through protein digestion with different 
enzymes such as trypsin, Lys-C, Asp-N, and Glu-C (Figure 1-4). [58] Recently,  -
sheathless capillary electrophoresis has been introduced for coupling to electrospray 
ionization tandem MS (CESI-MS/MS) to assess biosimilarity of mAbs as a replacement 
for LC.[59,60] In addition, amino acid analysis coupled with LC or capillary 
electrophoresis-electrospray ionization-tandem mass spectrometry (CESI-MS) can be 
used to determine amino acid composition and protein content and to detect atypical 
amino acids such as norleucine and hydroxyproline. [61–63]  
 
Figure 1-4 Overlay of HPLC chromatograms from Lys-C digest peptide map digestion of 
innovator (EU and US) and biosimilar etanercept products. Images reproduced with permission 
from Ref. [73]. 
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1.4.2 Higher-order structure 
Proteins undergo folding in cells, forming higher order structures (HOS), which refer 
to the secondary, tertiary and quaternary structure of proteins. Proprietary manufacturing 
systems can result in HOS differences of biosimilars and any differences in HOS between 
the biosimilar and the innovator should be addressed by applying orthogonal and state-
of-the-art methods to set the basis for biosimilarity. [64]  
For the determination of secondary structure, fourier transform infrared 
spectroscopy (FTIR), far-UV circular dichroism (CD), x-ray crystallography and nuclear 
magnetic resonance (NMR) are typically used. Among them, FTIR and CD are most 
commonly used to compare the innovator and biosimilar structural content of α-helix, β-
sheet and random coils. [54,55,65–70] FTIR spectroscopy can be used regardless of the 
physical state of the samples (solid/liquid, crystalline/non-crystalline, aqueous/organic 
solution and film/dispersion), with no limitation on protein size and requiring a relatively 
small amount of sample (10-100 µg) while providing a high signal to noise ratio, allowing 
data collection in as little as 10 ms. [71,72] CD provides data in a short time period (few 
hours) and with small amounts of sample (<20 µg),but requires that samples be in 
aqueous solution. Particularly for far-UV CD spectrum, absorption is derived from the 
peptide bond region (<240 nm) [73], therefore allowing conformational information, such 
as α-helix, β-sheet and random coil structures, to be obtained from characteristic CD 
spectra as well as secondary structural estimation using various algorithms (Figure 1-5A). 
[74] X-ray crystallography can be used for secondary structural analysis with high 
sensitivity and specificity, but is not optimal for routine analysis  due to its time consuming 
nature and because samples must be crystallized, which is not always achievable. [75,76] 
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Similarly, NMR generates useful protein secondary structural data but requires high 
sample concentration due to the lack of active isotopes present in the protein drug 
molecule and is time consuming. Due to the complex structure of large molecule protein 
drugs, 1-D NMR is typically used more for smaller biopharmaceuticals and can be used 
as a fingerprint comparison to show the structural similarity between innovator and 
biosimilar products. [77–79] These techniques can provide useful information on the 
entire folded structure, but lack sensitivity in relation to specific residues when compared 
to other HOS analysis methods. [80] 
Tertiary structure can be determined through near-UV CD, differential scanning 
calorimetry (DSC), 2D-NMR, antibody array, and intact mass spectrometry, such as 
hydrogen deuterium exchange MS (HDX-MS) and ion mobility MS (IM-MS). Near-UV CD 
(250-320 nm) can detect differences in the tertiary structural environment of disulfide 
bonds and aromatic residues, which are highly sensitive to their environment. [73,81,82] 
DSC is widely used to evaluate thermal and conformation stability of proteins during 
processing and manufacturing. [83–85] Highly similar DSC thermograms and Tm denote 
the similarity of tertiary structures as a result of thermal stability (Figure 1-5B). Recently, 
2D-heteronuclear single quantum coherence (HSQC) NMR, which measures the coupling 
of two different nuclei present on one bond, has been utilized to provide sensitive, robust 
and precise structural assessment of biologics. This technique has not yet been widely 
applied to mAb biosimilars due to their large size, although several biochemical strategies 
have been investigated in order to overcome this limitation. [86] 1H-15N HSQC was used 
to show the correlation of nitrogen and amide protons within the conformation along the 
polypeptide chains of innovator and biosimilar filgrastim (Figure 1-5C). [78,87–90] 
 12 
However, 2D-NMR requires highly concentrated samples and a long acquisition time to 
attain a large enough signal from the naturally low abundant levels of 15N and 13C present 
in the protein’s native state. [91] Antibody array utilizes binding of polyclonal antibodies 
against peptide fragments of a target mAb and is a highly sensitive and specific tool to 
detect regional changes in HOS at the molecular level and has a similar setup to sandwich 
ELISA. [54,91–96] HDX-MS can monitor conformational protein dynamics, relying on the 
deuteration of labile hydrogen in amide bonds along the polypeptide backbone followed 
by online pepsin digestion, LC separation and MS analysis. [76] Subtle differences in 
HOS can be detected, depending on the degree and rate of deuterium exchange of the 
same fragments between innovator and biosimilar products (Figure 1-5D and E). 
[54,55,97] The advantages of HDX-MS are its analytical capacities of complex buffer 
systems, large proteins, and its minimal sample requirement (5-100 pmol). [98] IM-MS is 
a rapid (msec) and sensitive (nmol) emerging technique for generating HOS fingerprints 
for biologics. [56,99–101] In addition to IM-MS, collision induced unfolding (CIU) has been 
applied for structural analysis, which is subsequently analyzed by IM-MS. CIU fingerprints 
yield distinct gas-phase unfolding patterns of proteins as a function of collisional heat so 
that small variations in protein structure can be easily resolved, something that is hard to 
achieve by IM alone. [99,102–104] Recently, CIU was utilized for a comparative study of 
innovator and biosimilar infliximab and showed highly comparable gas-phase unfolding 




Figure 1-5 Examples of methods that compare higher order structure. A) CD overlay 
spectrum of innovator and biosimilar infliximab in the far-UV region (190-250 nm). Adapted with 
permission from Ref. [55]. MRE: Molar Residue Ellipticity, RMP: Reference Medicinal Product B) 
DSC thermal stability overlay plot of innovator and biosimilar infliximab products. Adapted with 
permission from Ref. [55]. C) 2D NMR overlay plot of innovator and biosimilar filgrastim. Adapted 
with permission from Ref. [86]. D) HDX-MS generated butterfly plot of deuterium incorporation 
profiles and E) deuterium uptake difference plot of a heavy chain of innovator and biosimilar 
infliximab. Adapted with permission from Ref. [97]. F) IM-MS generated collision induced 
unfolding (CIU) fingerprints showing the averages [left] and standard deviations [right] of innovator 
[top] and biosimilar [bottom] infliximab products. Adapted with permission from Ref. [53]. 
 
1.4.3 Product variants 
While sequencing predicts the primary amino acid sequence of biologics, the 
precise structure of an active form cannot be determined until it is isolated and purified 
due to post translational modifications (PTMs) generated during in vivo [76,105] and in 
vitro manufacturing steps leading to inherent variability. [106–108] The most abundant 
and common modifications regarding biologics are glycosylation, amino acid 
modifications, and charge variants. [108,109] PTMs can directly and indirectly alter 
 14 
activity and immunogenicity of biologics, thus investigation of any PTM is necessary. 
[105,110]  
 Glycosylation, the addition of sugar moieties (oligosaccharides/glycans) to 
proteins in endoplasmic reticulum and golgi apparatus, is one of the most prevalent PTMs 
in eukaryotic cells, such as mammalian cell lines, and induces significant heterogeneity. 
Differences in glycoform profiles depend on both the expression system and 
manufacturing process, and can affect various biologic functions such as PK, PD, 
immunogenicity and biological activity depending on their composition (Table 1-3). [111] 
For example, the scale-up of adalimumab manufacturing processes led to differences in 
galactose and mannose glycoforms. [112] Glycan analysis for biologics can be performed 
at three levels: intact glycoprotein, glycopeptide and released glycan analysis. 
Table 1-3 Impact of glycoforms on the PK/PD of mAb biologics. [167] 























Accelerated mAb blood clearance[128,129] 
→ lower mAb exposure 
Enhanced FcγRIIIa 
binding/ADCC[130,131] 
Decreased C1q binding/CDC 
[130–132] 
Sialylated glycan 
Decreased clearance of Fc fusion proteins. 
→ higher exposure (high Cmax, high AUClast)[133] 
Anti-inflammatory[132,134–138] 
 
Intact glycoprotein and subunit analysis (for mAbs) by top-down approaches, such 
as a high-resolution MS system, can provide a quick estimation on the glycoform 
heterogeneity of biologics (Figure 1-6A-C). In the same manner, subunit analysis, with 
the usage of enzymes, such as IdeS to get Fc and F(ab’)2, can provide information on 
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subunit specific glycosylation. These are useful to evaluate and control manufacturing 
processes and batch-to-batch consistency with minimal sample preparation and short 
analysis times. [139–141] However, these analyses cannot provide information on the 
presence of minor glycoforms. [141] Glycopeptide analysis provides information of 
glycoform micro-heterogeneity and site-specific protein glycosylation sites (Figure 5D-F). 
[142] Similar to bottom-up approaches, glycoproteins are digested into glycopeptides and 
then analyzed, typically by LC-MS or MS/MS systems. RP and hydrophilic interaction 
liquid chromatography (HILIC) columns are commonly used for LC separation. To 
overcome the low abundance of glycopeptides in a complex digest mixture, glycopeptide 
enrichment is employed to increase abundance and specificity prior to MS analysis. 
[143,144] Then, various glycan databases and search engines are applied to screen and 
identify glycopeptides from complex sample data. [145–149] To generate the quantitative 
glycan profiles[141], endoglycosidases (e.g., PNGaseF, reductive alkaline) are commonly 
used to release glycans that are then analyzed with or without derivatization. 
[54,79,96,150–153] The most widely used platform is the labelled glycan workflow, 
glycans are fluorescently labeled, purified and then injected on an HILIC column and 
detected by a fluorescence detector and further confirmed by MS (Figure 1-6G). [154] 
Nowadays, there are several kits and also automated systems available for the released 
glycan analysis that provide faster and simpler steps for sample preparation at high levels 
of sensitivity. [155,156] To avoid concern about minor sialic acid loss during fluorescent-
labeling [157], label-free glycan workflow is available using a high-performance anion 
exchange chromatography coupled with pulsed amperometric detection (HPAEC-PAD). 
[96] PAD is highly specific for glycan analysis with separation by charge and size, requires 
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only pmol of sample and is available for the analysis of monosaccharide composition. 
[158–160] However, the lack of commercial standards for highly branched glycans can 
be a limiting factor for complete glycan mapping. [161] 
 
Figure 1-6 Examples of methods that compare innovator and biosimilar glycosylation 
profiles. A) Full MS mAb spectrum B) Enlarged inset of two continuing charge states from A. 
Adapted with permission from Ref. [162]. C) Mirror plot comparing deconvoluted masses between 
innovator and biosimilar mAb. Images reproduced with permission from Ref. [163]. D) LC-MS/MS 
N-glycan quantification of infliximab innovator infliximab. Calculated % of E) mannose terminated 
and F) afucosylated species from D. Images reproduced with permission from Ref. [53]. G) HILIC 
chromatograms comparing released N-linked glycans of innovator and biosimilar infliximab. 
Adapted with permission from Ref. [97]. H) Mass spectra comparison of  the 19+ charged Fab 
regions of innovator and biosimilar infliximab (Apo+1S to Apo+5S corresponded number of 
glycations) I) Relative intensity comparison of Fab glycation between innovator and biosimilar 
infliximab. Adapted with permission from Ref. [53]. 
 
During cell fermentation, purification, formulation and storage, biologics can be 
modified via PTMs (enzymatic reaction) or chemical modifications (non-enzymatic 
reaction) resulting in amino acid modifications such as oxidation, deamidation, 
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pyroglutamate (pGlu) formation and charge variants. [164,165] Both enzymatic and non-
enzymatic modifications may result in a significant effect on biologics’ quality, safety and 
efficacy. Oxidation is correlated with the propensity of aggregate formation [166–170], 
and the loss of function of various proteins. [171,172] For IgG1 and IgG2, several studies 
have reported that methionine (Met) oxidation in the Fc domain is related to decreased 
neonatal Fc receptor (FcRn) binding, which is related to IgG recycling and transcytosis. 
[173] Due to the proximity of Met residues to the FcRn binding interface, Met oxidation 
disrupts antibody conformation and IgG oligomerization, both of which are necessary for 
C1q binding and CDC activity, resulting in reduced binding and activity. [174–177] For 
example, filgrastim has 4 Met residues at positions 1,122,127 and 138, where oxidized 
variants at positions 122,127 and 138 showed reduced potency by an in vitro proliferation 
assay, likely due to the proximity of these positions to the binding sites in the granulocyte 
colony stimulating factor (G-CSF) receptor. [78] 
 Deamidation,  the cyclization of asparagine (Asn) residues to form either aspartic 
acid (Asp)/isoaspartic acid (Iso-Asp), frequently occurs depending on the primary 
structure of nearby amino acid residues, tertiary structure, storage temperature, and 
properties of formulation solution such as pH, buffer and ionic strength. [178,179] 
Glutamine (Gln) can also be deamidated but is hardly detected in recombinant biologic 
products due to the 100-fold slower reaction rate. [180] Deamidation is a main cause of 
chemical degradation and may introduce negative charge and potential local charge 
structure distortion. [181,182] It has been reported that deamidation at Asn 30 in the light 
chains of the trastuzumab innovator (Herceptin®) showed a potency reduction of 70% 
[183], with Asn 55 deamidation showing a 14-fold decrease in antigen binding affinity. 
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[182] Furthermore, Iso-Asp is a non-natural amino acid residue, and therefore potentially 
immunogenic. [184] To characterize amino acid modifications, the most widely used 
method is digestion followed by peptide mapping by LC-MS or MS/MS, similar to primary 
structure characterization (Figure 1-7A, B). [182,185–188] Many amino acid variants can 
also be classified as charge variants and are commonly observed in biologic products, 
especially mAbs. For example, succinimide formation and C-terminal Lys generate basic 
variants due to an addition of the positive charged amine, while deamidation and N-
terminal terminal pGlu formation generates acidic variants due to a loss of the positively 
charged primary amine. [189,190] It has been shown that these changes in pGlu and 
charge variants do not have significant clinical impact, but these modifications need to be 
monitored and identified because the introduction of heterogeneous species reflects a 
lack of manufacturing process control. [55,191–193]  Characterization of charge variants 
for biosimilar approval is generally performed by ion exchange chromatography (IEX) and 
CE-based methods such as isoelectric focusing (cIEF), imaged cIEF (icIEF) and capillary 
zone electrophoresis (CZE). [96,150,151,194] IEX separates proteins according to their 
overall net surface charge and even differentiates isoforms with single charge residue 
differences. [195–198] To further identify the nature of each peak separated by IEX, 
subsequent MS analysis is necessary. Proteins with high isoelectric points (pI), such as 
mAbs, are generally separated by cation exchange chromatogram (CEX) (Figure 1-7D). 
[196,199–201] CE-based methods in combination with MS can provide a more rapid 
analyses than IEX, while utilizing only small amounts of samples and reagents. [202] 
Recently, several technical challenges on CE-MS have been solved such as automation 
and ESI compatibility. [203–205] cIEF separates proteins based on their isoelectric points 
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(pIs) in a capillary, but requires a mobilization step that can cause peak broadening, 
resulting in increased run time, reduced resolution and poor reproducibility. [206,207]  
icIEF attempts to overcome this issue by scanning the entire capillary without the need of 
the mobilization step. [208–210] CZE separates proteins based on electrophoretic 
mobility (mass-to-charge ratio) with the application of an electric field between a cathode 
and an anode. However, charge variants can have highly similar molecular masses, thus, 
separation mainly occurs based on their charge. [211–213] Unlike cIEF, in CEZ, peaks 
are detected at 200-220 nm which can provide  higher sensitivity while preventing 
over/under estimation of charge variants with different UV absorption profiles at 280 nm. 
[214,215] 
 
Figure 1-7 Methods to detect amino acid modification. A) Extracted ion chromatograms 
of innovator and biosimilar trastuzumab of asparagine deamidation after tryptic digestion and LC-
MS analysis. B) Extracted ion chromatograms of innovator and biosimilar trastuzumab of c-
terminal lysine truncation after tryptic digestion and LC-MS analysis. Adapted with permission 
from Ref. [216]. C) Reverse phase HPLC chromatogram of innovator (after/before expiry) and 
biosimilar filgrastim oxidation, with each oxidized peak confirmed by fragment ion analysis. 
Images reproduced with permission from Ref. [188].  D) Charge variants analysis of innovator 
and biosimilar rituximab by CEX-HPLC. Images reproduced with permission from Ref. [201]. 
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1.4.4 Impurities 
In the course of manufacturing and during storage, biologics may obtain impurities, 
product and process related, which can affect the final products’ stability safety and 
efficacy. Product-related impurities are undesired modifications such as disulfide bond 
variants, glycation and aggregation while process-related impurities correspond to 
materials used in the production process such as cell culture, extraction and purification 
steps. [217] These impurities differ from product variants which are considered 
comparable to the biologic product. [218]  
Disulfide bonds are product-related impurities that play a critical role in biologics 
both structurally and functionally, facilitating protein HOS folding and stabilization. 
[219,220] Disulfide bonds link the light and heavy chains via inter-chain bonding and 
stabilize subdomain folding via intra-chain bonds. [221] The heterogeneity of recombinant 
mAb disulfide bonding has been previously reported. [189,222,223] Incorrect disulfide 
bonding, such as breakage and scrambling can occur when biologics are exposed to 
environmental stresses during downstream processing steps. [224,225] Thus, it is 
essential to evaluate the presence of expected and unexpected disulfide bonds, which 
reflects protein misfolding or aggregation and can lead to changes in potency and safety. 
For example, etanercept, and its biosimilar have complex disulfide patterns with 29 
disulfide bridges throughout their structures and are known to have incorrect disulfide 
variants between specific cysteines in the receptor domain, leading to changes in their 
potency (Figure 1-8A, B). [79,226,227] To characterize disulfide bonding, non-reducing 
peptide mapping using a RP-LC-MS or MS/MS system is regarded as the standard 
method. Peptide fragments retaining a single disulfide bond are generated using 
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enzymatic digestion and separated by RP-LC and subsequently confirmed by MS or 
MS/MS. [228–230] Indirectly, the presence of cleaved disulfide bonds can be further 
quantified by free cysteine (thiol) analysis using Ellman’s reagent as a colorimetric 
method. [151,231]  
Glycation is the attachment of reducing sugars to the primary amine of proteins, 
which are typically Lys residues. [232,233] For biologics, glycation mainly occurs on mAb 
products during cell fermentation and storage, where sugars are a source of energy and 
a main ingredient. [234–236] It is known that glycation can reduce biologic activity and 
stability of recombinant proteins depending on their binding site and cause the loss of the 
positively charged Lys residue, resulting in charge variants. [237–241] The two main 
methods to analyze protein glycation are boronate affinity chromatography (BAC) and 
LC-MS. [53,69,79,96,151] In BAC, boronate groups in the column retain glycated proteins 
at high pH conditions, which are then eluted out by either decreasing the pH, or by adding 
a competing sugar agent, such as sorbitol. [234] However, glycosylated proteins can be 
retained on BAC columns, which may lead to non-specific binding [242,243] and 
quantitative data is not provided since it cannot differentiate between proteins with single 
and multiple glycations. [240] Various top-down and bottom-up LC-MS based methods 
can be used for glycation analysis, which are highly similar to the approaches used for 
glycan analysis. Top-down approaches provide a quick characterization of glycation 
levels after deglycosylation and the removal of C-terminal Lys by detecting +162Da mass 
shifts (Figure 1-6H, I). [53,96,244] Bottom-up approaches can provide information on 
glycation sites by detecting missed tryptic cleavage sites that have +162Da mass shifts 
since the glycation of Lys residues blocks tryptic digestion. [236,245] Each method has 
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different sensitivities and therefore comparisons cannot be made across methods. Most 
analyses are being done with MS technologies.  
 
Figure 1-8 A) Correlation of % potency (TNF-α neutralizing activity) with % incorrect 
disulfide bonding at C78-C88 for etanercept. B) Structure of etanercept with correct and incorrect 
disulfide bonding. Images reproduced with permission from Ref. [246]. 
 
Another major challenge in producing biologics is their natural propensity to 
aggregate.[76] These aggregates vary in size (nm-μm), structure (native/non-native), 
morphology  (spherical/fibrillar/amorphous), and their reversibility. [247] Not only does the 
presence of protein aggregates compromise therapeutic efficacy and bioavailability, but 
they may elicit immune responses to the protein drug, even generating anti-drug 
antibodies (ADA). [248–252] The elicited immune response results from the combination 
of one or more changes of solubility [249], viscosity [253] and exposure of neo-epitopes, 
induced by conformation alteration, considered as foreign by the immune system (Figure 
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1-9A). [254] In the case of the infliximab biosimilar, there have been reports that 
aggregates might affect TNF-α binding which is a critical mechanism of action and 
potential for immunogenicity. [96] However, there is no single method that can assess a 
wide size range of aggregates (Figure 1-9B). Therefore, biosimilar developers should 
analyze aggregates by employing several orthogonal methods for cross-validation to 
ensure the presence of comparable or lower levels of aggregates with the reference 
throughout the product’s life-cycle, manufacturing, storage and delivery. Among the 
diverse methods of aggregate determination, size exclusion chromatography (SEC) is the 
most commonly used analytical method for quantification and size estimation of 
aggregates (Figure 1-9C). SEC is based on molecular sieving, which separates from 
larger to smaller molecules depending on their molecular size in solution. [247] In 
addition, SEC can be combined with UV, fluorescence, multi-angle laser light scattering 
(MALS) and other detectors. SEC-MALS provides increased accuracy by acquiring 
absolute molar mass for each eluted fraction over SEC or MALS alone. [255] However, it 
has been reported that SEC can incorrectly detect aggregates due to either unwanted 
secondary interaction with the stationary phase (adsorption) [256], removal of large 
insoluble aggregates during sample preparation, or dissociation of reversible aggregates 
during dilution. [257,258] Asymmetric flow field-flow fraction (AF4) determines particle 
size by laminar and perpendicular cross-flows through a liquid across two different plates, 
separating particles depending on the particle diffusion coefficient. [259] AF4 can be 
combined with various detection methods such as UV, MALS and refractive-index. [260] 
However, method validation can be difficult and possible dissociation of aggregates can 
also occur during dilution. [257]  Analytical ultracentrifugation (AUC) is another commonly 
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used method for size detection and can be utilized in two different ways, sedimentation 
velocity (SV), a hydrodynamic approach, and sedimentation equilibrium (SE), a 
thermodynamic approach. In general, AUC separates particles of various shape and sizes 
by centrifugal force and by detection with attached optical systems 
(absorbance/interference/fluorescence) (Figure 1-9D). The biggest advantage of AUC is 
the ability to directly measure aggregates in various native solutions and over a wide 
range of sample concentrations. [261] While useful for absolute size measurements, AUC 
is low-throughput, requires high quality instrumentation and complicated data analysis. 
[247,262] Dynamic light scattering (DLS) and nanoparticle tracking analysis (NTA) 
measure particle diffusion coefficients based on Brownian motion and light scattering. 
DLS is a useful tool for fast size assessment, providing a wider range of particle size and 
sample concentrations than NTA. DLS requires low sample volume (μL) and samples can 
be easily collected for further analyses. DLS generates an intensity distribution of particle 
sizes (Figure 8E), which is sensitive to the presence of larger particles like contaminants 
and aggregates that may dominate light scattering signals, resulting in misrepresented 
particle size distributions. [247,263,264] NTA tracks and visualizes movement of particles 
using a microscope coupled with a camera system providing size distribution 
representative of number distribution. Compared to DLS, NTA generates information on 
particle concentration in solution with a better resolution on samples with polydisperse 
size distribution. However, NTA often requires sample dilution to analyze, which will in 





Figure 1-9 A) In vitro interactions of protein aggregates with antigen presenting cells 
(APCs) that can potentially trigger an immune response through different kinds of receptors -  
FcγRs, TLRs and/or CRs. In addition, following the receptor mediated phagocytosis of 
aggregates, lysosome digested peptides are presented on the cell surface that stimulates naïve 
T-cells. Adapted with permission from Ref. [254]. B) Size-dependent analysis methods of various 
aggregates and particle sizes. C) Comparison of SEC chromatograms and D) sedimentation 
coefficient distribution plots between innovator and biosimilar infliximab. Images reproduced with 
permission from Ref. [54]. E) DLS particle size distribution plots of innovator and biosimilar mAbs 









 Functional assays for biosimilarity assessment 
The functionality assessment of a biosimilar product is as important as 
physicochemical property assessment. Physicochemical assessment does not provide 
information on the functional capabilities, but rather, provides only structural and physical 
information for molecules. It is critical to validate that no structural differences may lead 
to meaningful clinical efficacy and safety implications. To demonstrate this, multiple 
functional assays such as, but not limited to, ligand-binding assays (LBA) and cell-based 
assays (CBA) must be developed to adequately assess biosimilarity. For this reason, the 
FDA and EMA have been developing a regulatory guidance recommending multifactorial 
and stepwise approaches to demonstrate and assess biosimilarity. [26,64,268] The goal 
of functional assessment is to verify that any structural differences identified from 
physicochemical assessment do not result in differences in pre-clinical/clinical testing. 
1.5.1 Ligand binding assay 
The large portion of biosimilars under development and innovator products that 
are close to off-patent are mAbs whose therapeutic effect relies on binding to specific 
target sites. Hence, LBAs become more critical in biosimilar development to validate 
whether specific binding sites correspond to those of the innovator product. LBAs provide 
the measurement of interactions between antibody and antigen such as strength of 
binding affinity. [269] Although LBAs do not provide as comprehensive information on 
biosimilarity as CBA and in-vivo assessments do, they are useful as an early evaluation 
during development. 
There are two general methods for assessing ligand-binding analysis: ELISA, a 
solid phase assay, and surface plasmon resonance (SPR), a kinetic binding assay. 
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Generally, ELISA uses a sandwich approach where coated capture antibody binds to 
target analyte which can later be detected by detection antibody conjugated with HRP. 
[270] ELISA is not only used to demonstrate the binding between mAb and analytes, it is 
also commonly used to measure other bindings such as binding of C1q and the Fc-
domain which plays a key role in activation of complement-dependent cytotoxicity (CDC). 
[271] ELISA has been a preferred method due to the use of standard instrumentation and 
materials in addition to a broad familiarity with the technology while still providing high 
sensitivity and specificity. However, ELISA can be labor-intense, time-consuming, and 
provokes intra- and inter-assay variation through multiple pipetting and washing steps 
making them potentially unreliable as standardized assays. [272]  
AlphaScreen and AlphaLISA are newer forms of immunoassays where biotinylated 
antibody and antibody-conjugate AlphaLISA acceptor beads are used to capture the 
target analyte (Figure 1-10A, B). Donor beads coated with streptavidin capture an 
analyte-specific biotinylated antibody while acceptor beads that are conjugated with a 
secondary antibody can readily recognize the different epitope of the analyte. This binding 
recruits donor beads and acceptor beads within 200 nm proximity of each other, allowing 
excited donor beads to release singlet oxygen that can excite a fluorescent signal in the 
acceptor beads. [273,274] Currently, few studies have used the AlphaLISA assay to 
measure relative bindings to Fc domain including FcγRIa, FcγRIIIa (158V), and FcγRIIIa 
(158F). [270,275] Compared to ELISA, AlphaScreen/AlphaLISA is more high-throughput, 
requires a lower sample volume while offering a wider analytical range and is more 
sensitive than other preceding immunoassays. [274] AlphaScreen technologies also do 
not require a wash step which can preserve biological interaction. [274] However, 
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AlphaScreen/AlphaLISA is sensitive to long exposure to ambient light, donor beads can 
photo bleach which limits it to a single reading, singlet oxygen can be sequestered by 
compounds that could scavenge radical oxygen, and it is not adaptable to all plate readers 
like ELISA. [274] The assay to assess the binding of FcRn to mAb was developed on the 
AlphaScreen platform which was found to be more accurate, precise, specific, and simple 
compared to ELISA, fluorescent-activated cell scan, and SPR.[276] Similar to AlphaLISA, 
FcRn-loaded donor beads and IgG1-loaded acceptor beads are incubated with mAb and 
dose-dependent decreases in emissions are monitored (Figure 1-10A, B).  
SPR is a real-time, label-free (RT-LF) platform that is widely used for ligand binding 
analysis along with ELISA. However, unlike ELISA, SPR monitors the association and 
dissociation of binding complexes in real-time to measure the binding kinetics, affinity, 
and binding specificity of Fc-receptors with their targets, including FcRn, FcγRIIa, 
FcγRIIb, FcγRIIIa, and FcγRIIIb. [68,96,275] In SPR, sample is flowed over the surface 
of a sensor chip that is coated with analytes such as target molecules or Fc receptors and 
changes in refractive index are used to determine the association rate constant (ka), 
dissociation constant (kd), and dissociation equilibrium binding constant (KD) of antibody-
antigen interactions. [277,278] SPR collects kinetics of binding data whereas ELISA 
collects end-point binding data. Therefore, SPR can provide more comprehensive data 
collection than ELISA. SPR does not require any labeled reagents or wash steps and it 
does not require standards like ELISA, where assay results are dependent on the 
functional quality of the standards. [279] SPR uses calibration-free concentration analysis 
(CFCA) which does not require a standard curve while relying on changes in binding rate 
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with varying flow rates, when the rate is limited by analyte diffusion on the sensor surface 
(Figure 1-10C, D). [280–282]   
Bio-Layer Interferometry (BLI) is relatively newer RT-LF platform that has more 
potential to support high-throughput demands in current pharmaceuticals. [283,284] BLI 
is an optical analytical technique that uses dip and read biosensors to measure the 
interference patterns of light caused by a binding between molecules in solution and 
molecules immobilized on the biosensor tip surface (Figure 1-10E). Compared to SPR, 
BLI is relatively robust to fluctuations in the refractive index, is free of microfluidics, and 
is capable of high-throughput analysis. [285]  
 
Figure 1-10 Methods for the determination of ligand binding. A) Comparing FcγRIIIa 
binding affinity competition of mAbs A) in the presence of (left) or not in the presence of 
biotinylated competitor mAb (right) using AlphaScreen or AlphaLisa. B) Comparison of dose 
response curves of innovator and biosimilar adalimumab showing FcγRIIIa (158V) binding (in the 
presence of TNF-α) using AlphaScreen. Adapted with permission from Ref. [270]. C) Principle of 
SPR analysis for target binding. Adapted with permission from Ref. [286]. D) Comparison of target 
binding between innovator and biosimilar filgrastim by SPR. Images reproduced with permission 
from Ref. [77].  E) Principle of BLI to measure target binding affinity of mAbs As more molecules 
bind to the biosensor surface, the wavelength shift of the reflected light will be shown on a 
sensorgram. Adapted with permission from Ref. [287]. 
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Figure 1-11 Cell based bioactivity assays. Mechanism of NFκB-dependent luciferase 
reporter gene assay for measuring Fab mediated TNF-α neutralization A) with (upper) or without 
(bottom) anti-TNF-α mAb. B) Comparison of dose-dependent TNF-α neutralization activities 
between innovator and biosimilar etanercept. Images reproduced with permission from Ref. [288]. 
C) The assessment of effector functions induced by Fc domain – ADCC, CDC and ADCP. ADCC 
is mediated by FcγRIIIa, CDC is mediated by C1q, and ADCP is mediated by FcγRIIa with 
antibody to induce cell death. MAC: Membrane Attack Complex. 
 
 Cell-based bioactivity assay 
The mechanism of actions (MoA) and stimulation of downstream signaling events 
of each therapeutic mAb varies. Therefore, a bioactivity assay is required to evaluate the 
MoA which cannot be assessed by non-cellular ligand binding analyses. MAb Fab-
domains display variable sequences that associate with antigen binding specificity and 
are directly related to the MoA, including neutralization, induction of apoptosis, or growth 
inhibition. The Fc-domain exhibits a constant sequence that is responsible for triggering 
effector functions such as complement-dependent cytotoxicity (CDC), antibody-
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dependent cell cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis 
(ADCP). [289] Therefore, it is important to have comprehensive assessments of both the 
Fab domain and Fc domain to validate the function and similarity of biosimilars. CBA are 
chosen and developed based on the reported MOAs and are unique to each 
biosimilar/reference pair.  
The bioactivity assessments of Fab domains are well-established for mAbs, 
especially for mAbs whose biological function is primarily contributed by the Fab-domain, 
such as infliximab and adalimumab which inhibit pro-inflammatory signaling induced by a 
target protein TNF-α via the Fab-domain. Fab functionality assessments typically include 
cell binding assays and neutralization assays. The results of competitive cell-based 
assays can be informative to assess the similarity of biosimilar and reference mAb with 
respect to binding to TNF-α and can also characterize the binding function of the Fc-
domain. Cell-based functional bioassays such as CD20 binding, Fc-effector function, and 
apoptosis activity were used to assess originator rituximab and its biosimilar. [68] To 
further characterize binding function, a neutralization assay can be used to assess the 
similarity of the biological functions that contribute to the clinical efficacy such as TNF-α 
and LT-α neutralization. Neutralization activity can be determined via apoptosis, 
cytotoxicity, or reporter gene assays. In a study of adalimumab biosimilar, ABP 501, 
inhibition of TNF-α-induced apoptosis was evaluated since TNF-α can induce apoptosis 
under the conditions in which activity of NF-κB is reduced. [270] Etanercept biosimilar, 
GP2015, compared its neutralization to reference using a reporter gene assay (Figure 1-
11A, B). [79,288] Inhibition of target cell growth by blocking signaling pathways in cancer 
cells is one of the many modes of action for cancer therapeutic mAbs. [290] Therefore, 
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many biosimilars of antiproliferative therapeutic mAbs apply this approach to assess the 
potency of its inhibition of target cell growth. ABP 215 and its innovator, bevacizumab 
were evaluated for their similarity in antiproliferative function by using adenosine 
triphosphate (ATP)-specific luminescent reagent combined with lysed cell to determine 
the viability of the cell through amount of ATP presented. [275]  
The assessment of effector function induced by the Fc-domain is necessary for 
therapeutic mAbs, especially those that Fc-effector functions have been proven to be part 
of their MOAs. To assess CDC activity, target cells and therapeutic mAbs are incubated 
and complement is introduced to opsonize target cells and induce lysis while monitoring 
cell viability by luminescence, fluorescence or ATP production with various commercially 
available reagents. [68,270,291] ADCC assays depend on mAb-mediated cross-linking 
of target cells and effector cells via binding with FcγRIIIa receptors on effector cells. 
Purified human natural killer (NK) cells are most widely used as effector cells in ADCC 
activity assessments, however, to more closely replicate the physiological environment, 
peripheral blood mononuclear cells can be used as effector cells since they are more 
representative of in vivo conditions including range of cell types and immune complexes. 
[96] ADCC cell death can be monitored through detection of prelabeled cells or production 
of cytosolic enzymes. [291] Successful ADCC assays require an optimization of the ratio 
of target cells to effector cells as the density of FcγRIIIa differs from donor-to-donor cell 
population. [292] Lastly, as the FcγRIIIa allotypes have different binding affinity against 
Fc domains of therapeutic mAbs, it is critical to compare the activity in both V/V and F/F 
genotype of FcγRIIIa. [293,294] Rituximab originator and adalimumab originator and their 
biosimilars were both evaluated for CDC and ADCC using methods described above. 
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[68,270,295] Cell-based assays can also be used to assess biosimilars such as filgrastim, 
a granulocyte colony-stimulating factor, which is not a mAb. Filgrastim bioactivity was 
assessed by incubating filgrastim with target cells, NFS-60, and luminescence was used 
to compare potency of each compound. [296] Although cell-based assays offer valuable 
knowledge of  biosimilar functionality, they can be time-consuming and highly variable 
due to many extrinsic variables such as the assay matrix and are often difficult to validate. 
[297] (Figure 1-11C)  
 Forced degradation studies 
Forced degradation studies have been utilized to support the drug development 
process and to evaluate manufacturability. [298] These studies are performed by applying 
thermal (elevated temperature, Freeze/thaw), chemical (low/high pH, oxidizing condition) 
or physical (agitation) stresses to drug substances and drug products. [299] Objectives 
of these studies are the following. (1) to determine the degradation pathway, (2) develop 
formulations, (3) develop analytical methods, (4) determine shelf-life, (5) evaluate 
manufacturability, (6)  assess CQAs and (7) determine the intrinsic stability. [300] 
Recently, stresses have been utilized to compare biosimilarity as a comparative stability 
test in Biologic License Application submissions. [96,150,151,194,301] Analytical 
methods to assess degradation products are shown in Table 1-4. 
1.7.1 Major degradation pathways 
There are several major degradation pathways for mAbs. The most commonly 
observed pathways are (1) aggregation, (2) fragmentation, (3) deamidation and (4) 
oxidation. Under specific stress conditions, small amounts of impurities can be amplified. 
For example, levels of deamidation and disulfide bond scrambling can increase under 
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high pH conditions while levels of oxidation can increase under high- temperature 
conditions.  
Table 1-4 Selection of analytical methods to assess different types of degradation 
products 
Types of Degradation Selected Analytical Methods 
Soluble aggregation and fragments 
SEC-HPLC, AF4, AUC, SDS-PAGE, Capillary 
electrophoresis 
Subvisible aggregates, nanometer size range 
DLS, NTA, AF4, MALLS, Turbidity, Static light 
scattering 
Subvisible aggregates, micrometer size range Light obscuration 
Visible particles Visual inspection 
Secondary structure Far-UV CD, IR, Raman spectroscopy 
Tertiary structure 
Near-UV CD, Intrinsic fluorescence, NMR, 
Second derivative UV spectrometry 
Changes in hydrophobicity 
RP-LC, extrinsic fluorescent dyes, Hydrophobic 
interaction chromatography 
Chemical change (e.g, oxidation, deamication) LC-MS, Peptide mapping, RP-LC, IEX-LC, IEF 
 
1.7.2 Sources of stress 
The most common method of forced degradation studies is the application of high 
temperature (thermal stress) that exceeds the normal storage temperature. For example, 
mAb drug products are required to be stored from 2-8 °C. Thus, 25 °C and temperatures 
above 35 °C are used for accelerated stability studies. This facilitates the formation of 
degraded substances, such as aggregates and fragments over the course of a short 
period of time. When a drug substance is in a solid form (such as lyophilized mAb drugs), 
high humidity may also be introduced in addition to thermal stress. [338,339] 
Freeze-thaw is often utilized for forced degradation studies because drug 
substances can be exposed to low temperatures over the course of long-term storage 
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and lyophilization. This study is useful to assess drug stability upon accidental freezing 
and determine appropriates excipients that protect and stabilize the drug products during 
lyophilization.[340] The major degradation pathway for freeze-thaw is aggregation, 
including precipitation and particle formation. [341,342]  
Drug substances and products can encounter agitation (stirring or shaking) as 
physical stresses during the entire drug manufacturing process, filling, shipping, and final 
administration. Thus, it is crucial to confirm a drug’s robustness and stability against 
agitation. [340] Stirring, shaking, vortexing and sonication can be used for mechanical 
stress testing. [343–347] The major degradation pathway is aggregation after exposing 
the molecule to agitation.  
Drug substances such as mAbs can be exposed to low or high pH conditions 
during purification. Low pH leads to aggregation and fragmentation, especially in solutions 
where mAbs are found at high concentration, resulting in precipitation. [334] High pH 
causes asparagine deamidation and disulfide bond shuffling, resulting in aggregation and 
fragmentation. [348] 
During manufacturing, biologics are exposed to oxidizing condition by dissolved 
oxygen and free radicals derived from metal and oxidized surfactant impurities. Hydrogen 
peroxide and tert-butyl hydrogen peroxide are the most widely used reagents to test for 
forced methionine oxidation. Probing oxidation susceptible residues by forced oxidation 
is important since oxidation of site-specific residues (mainly Methionine) can result in 
decreased drug potency when the residue is located at the site of drug binding (antigen-
binding sites). Often oxidation can occur aggregation since oxidation induced-
conformation changes can occur. [334]   
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 Research scope  
My research contributes to a key foundational step in biosimilar development that 
requires extensive and robust analytical characterization to fill the gaps in knowledge 
resulting from the lack of disclosed information for innovator drug products. Through this 
research, one can characterize the quality attributes of a biosimilar and evaluate whether 
or not they closely match the structural and functional features of the originator. Based 
on the degree of similarity and residual uncertainty between an originator and a biosimilar, 
analytical characterizations can determine the extent of preclinical and clinical studies. 
The introduction highlights key characteristics of biosimilars including critical quality 
attributes and methods for analytical characterization of biosimilar structure and function. 
The work presented demonstrates the utility of various techniques to measure 
comparability between an originator and any prospective biosimilar.  
 Thesis overview 
The overall goal of this thesis is to demonstrate biosimilarity and shed light on the 
minor differences between originator drugs and their respective biosimilars. To do this, 
we have compared different originator and biosimilar pairs; filgrastim, rituximab, 
bevacizumab and trastuzumab, using various analytical techniques. This thesis is 
composed of 5 chapters showing comparability studies of each originator and biosimilar 
pair regarding structure and functional aspects.   
Chapter 2 of this thesis focuses on the analytical characterization of the originator 
filgrastim (Neupogen®) and its proposed biosimilar. This chapter first examines primary 
and higher order structures. This is accompanied by the analysis of variants that may 
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affect biological activity. Findings from this study can be used to support the claim of 
biosimilarity of a proposed biosimilar to filgrastim to a regulatory agency. 
Chapter 3 assesses the biosimilarity of Rituxan®, the originator rituximab and 
Acellbia®, a biosimilar, using MAM workflow that can measure several attributes in a 
single assay. Outside of MAM, several different MS and LC separation techniques are 
utilized to characterize the higher order structure and product-related variants of 
rituximab, respectively. This chapter identifies key differences between the originator and 
a biosimilar that could lead to different biological activities, such as ADCC.  
Chapter 4 evaluates the initial structural differences/similarities existing between 
three original mAb drugs and their biosimilars as well as their behaviors when subject to 
thermal stress. This stress condition could amplify subtle initial structural differences 
between the originators and biosimilars that might not be detected by individual analytical 
instruments. Findings from this work can be used when attempting to establish 
biosimilarity.    
Chapter 5 highlights the final conclusions of each chapter and discusses the 
future direction for this work. Each chapter was prepared in a manuscript format. 
Chapter 1 was prepared with an invited submission to Angewandte Chemie. Chapter 3 
was submitted for publication to European Journal of Pharmaceutics and 
Biopharmaceutics. Chapter 4 is written in a format for submission to Analytical and 
Bioanalytical Chemistry.
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Filgrastim (brand name: Neupogen®), a recombinant human granulocyte colony-
stimulating factor (rhG-CSF), is widely used to treat neutropenia by stimulating neutrophil 
maturation. Zarxio®, a filgrastim biosimilar, was the first biosimilar approved in the US due 
to its relatively simple structure compared to that of monoclonal antibody drugs. As of now, 
two filgrastim biosimilars have been approved in the US, but more may be approved in 
upcoming years. In this study, we compare Neupogen® and its proposed biosimilar 
regarding their structure (primary, higher order) and variants (size, oxidized, deamidated) 
using different mass spectrometry (MS) techniques, NMR and liquid chromatography (LC) 
techniques. No significant differences were detected regarding structure and variants levels 
except deamidation levels. 
 Introduction 
Filgrastim is a recombinant human granulocyte-colony stimulation factor (rhG-CSF) 
product that has the same biological activity as endogenous G-CSF. Unlike human G-CSF, 
filgrastim contains an N-terminal methionine (Met) residue and is not glycosylated as it is 
expressed in Escherichia coli. [324] Filgrastim is used to treat neutropenia, a condition 
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derived from cancer chemotherapy and several other disease states, by stimulating 
neutrophil maturation. [325,326] 
A biosimilar is a biological product that has no clinically meaningful differences from 
its reference product in terms of safety, purity and potency. [52] The market for biosimilars 
in the US has gained more attention, thanks in large part to the approval of the first 
biosimilar, Zarxio®. Zarxio®, a biosimilar filgrastim, was approved in 2015 and paved the 
way for the FDA approval of a second filgrastim biosimilar, Nivestim, in 2018. The number 
of biosimilars in development continues to rapidly increase due to the imminent patent 
expiration of many other biologic products and the release of an FDA guidance for 
biosimilar approval. However, dramatic cost savings for patients is highly unlikely due to 
the inherent requirement of more sophisticated procedures and higher operational cost for 
biologics, when compared to small molecule generics. [327] Contrary to small-molecule 
drugs, where the FDA provides an abbreviated regulatory pathway for generic drugs, 
biologics and their biosimilars present a difficult challenge in their regulatory pathway. The 
inherent complexity and variability in post-translation modifications (PTMs) observed for 
biologics and their biosimilars prevents the FDA from establishing an equivalent 
abbreviated pathway. [328] Therefore, the FDA encourages extensive fingerprint-like 
analytical assessment of biosimilars, as well as highly targeted animal and/or clinical tests, 
to ensure similarity between the biosimilars and their biologic reference product. In this 
regard, thorough characterization can provide the foundation allowing companies to 
determine the scope and extent of further animal and/or clinical tests [329]. While these 
assessments provide further confidence in the structure, potency and toxicity-based 
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similarities between biosimilars and reference biologics, they often come with the need to 
perform experiments using cutting-edge techniques and equipment. [52,67] 
There are many tools available for characterizing biosimilarity. The primary structure 
of therapeutic proteins can be determined via peptide sequencing and mapping, and higher 
order structures can be characterized using circular dichroism (CD) spectroscopy and 
differential scanning calorimetry (DSC). Commonly employed methods for identifying 
impurities in biologic products include LC, SDS-PAGE and LC-MS. Information on protein 
binding affinity and kinetics is typically obtained using bioassays (ELISA, AlphaLISA, etc.) 
and surface plasmon resonance (SPR). [82,330–332]   
In this study, we describe the physicochemical characterization of a potential 
filgrastim biosimilar and its reference product, Neupogen®, utilizing multivariate analytical 
techniques. Specifically, peptide mapping and PTM analysis were conducted to compare 
the primary structure of the products. Higher order filgrastim structures were compared by 
employing 1-dimensional (1D) and 2-dimensional (2D) NMR, ion mobility mass 
spectrometry (IM-MS) and intact mass spectrometry. Product impurity levels were 
evaluated using RP-UPLC and SEC UPLC analysis. 
 Materials and methods 
2.3.1 Materials 
Ammonium bicarbonate, acetonitrile (HPLC grade), dithiothreitol (DTT), 
iodoacetamide (IAM) and sorbitol were obtained from Fisher (Hampton, NH). Trifluoroacetic 
acid (TFA, for HPLC, ≥ 99.0%), formic acid (FA), sodium acetate, glacial acetic acid and 
deuterium oxide were purchased from Sigma-Aldrich (St. Louis, MO). Endoproteinase Glu-
C and Progenta™ anionic acid labile surfactant were obtained from Protea (Morgantown, 
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WV). The original filgrastim (Neupogen®, lot numbers (0.6 mg/ml - 1056459, 1061003, 
1057138), (0.3 mg/ml -  1048844, 1055570, 1050158) and biosimilar filgrastim (lot numbers 
(0.6 mg/ml - 3-Fin-2475, 3-Fin-2476, 3-Fin-2477) (0.3 mg/ml - 3-Fin-2479, 3-Fin-2480, 3-
Fin-2481(0.3 mg/ml)) were provided by Adello biologics. 
2.3.2 Enzymatic digestion 
For digestion, 20 μg of samples were diluted in 100 mM Ammonium bicarbonate (pH 
8.0) with 0.1% Anionic Acid Labile Surfactant. Proteins were reduced with DTT followed by 
1 hour of incubation at 37°C. Alkylation was performed by adding IAM at a final 
concentration of 10 mM. Samples were then incubated in the dark for 30 minutes at room 
temperature. IAM was quenched using DTT. Glu-C enzyme was added to make a 1:20 
enzyme to protein ratio after which the samples were incubated overnight at 30°C. 
Following digestion, samples were immediately acidified with FA and stored at 4°C until 
analysis. 
2.3.3 Peptide mapping 
We analyzed the protein digests using MS/MS on an Electrospray ionization (ESI) 
Q exactive mass spectrometer (ThermoFisher, Waltham, MA) interfaced with an Acquity 
UHPLC system (Waters, Milford, MA). LC separation was performed on an analytical 
column (AdvanceBio Peptide Mapping C18, 2.1 x 150 mm 2.7 μm) (Agilent, Santa Clara, 
CA) at a flow rate of 150 μl/min with a 50 min reverse phase gradient. The mass 
spectrometer was operated in a data-dependent acquisition mode. The 2 most intense 
multiply charged ions in each regular MS scan were subjected to MS/MS analyses. 
Precursor ions were scanned at 70,000 resolution, while fragment ions were scanned at 
17,500 resolution. Mass accuracy, sensitivity, and fragment isolation were assessed by 
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injecting 1 pmol of Pierce Peptide Retention Time Calibration Mixture prior to data 
acquisition.  Byonic™ search software was used for the analysis of LC-MS/MS data from 
digested samples. The precursor peptide mass was measured in the first stage of MS/MS 
(MS1), with the resulting fragment ion masses being measured in the second stage of 
MS/MS (MS2). Byonic™ analyzes peptide ions by matching the mass of the precursor 
mass (MS1) with the expected fragment ion masses (MS2) and its calculated masses 
based on an in-silico filgrastim sequence digest. Byonic™ can provide a search of variable 
modifications such as the oxidation of methionine and tryptophan residues and deamidation 
of asparagine and glutamine residues. 
Byologic® software employs a label free quantification approach, utilizing extracted 
ion chromatogram areas (XIC areas) to quantify PTMs with respect to their unmodified 
counterparts. XIC extraction and data organization were performed automatically by 
Byologic® using the data derived from Byonic™ search software. 
2.3.4 Ion mobility mass spectrometry 
Samples were buffer exchanged with 100 mM ammonium acetate using a 10K 
MWCO Microcon filter device. Sample aliquots (~7 µL) were analyzed in triplicate for each 
lot by IM-MS on a Synapt G2 HDMS quadrupole-ion mobility-time-of-flight mass 
spectrometer (Q-IM-ToF MS) instrument (Waters, Milford, MA). Protein was ionized by 
nano-ESI in the positive mode with a capillary voltage of 1.2 – 2.0 kV and cone voltage of 
60 V. To generate ion mobility separation, Direct Current (DC) voltage with 600 m/s of wave 
velocity and 40 V of wave height was applied.  
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2.3.5 Collision induced unfolding 
The ions gained collision energy in the traveling-wave-based ion trap prior to 
reaching the IM separator to carry out protein CIU. The 8+ charge state of the intact protein 
was chosen by tandem-MS using quadrapole selection. The collision voltage increases in 
a 5 V stepwise manner from 5 to 90 V to construct the fingerprint data, a profile of energy-
dependent arrival-time distribution.  
All mass spectra were processed using Masslynx 4.1 software. CIU data were 
extracted as a function of collision voltage and drift time using Drift Scope (Waters, Milford, 
MA). Analysis of Extracted CIU data was performed using CIUSuite. Corresponding 2D-
contour plots were generated by the CIUSuite_gen module where the strongest intensity 
was shown in red and normalized with a maximum value of 1 by a Savitzky−Golay filter. 
Average CIU fingerprints and standard deviation plots were generated for multiple lots of 
innovator and its biosimilar using the CIUSuite_stats module. 
2.3.6 1 and 2-dimensional NMR analysis 
Each sample (13 prefilled syringes - 480 µg of filgrastim each) were concentrated 
using pre-rinsed Amicon® Ultra centrifugal filter units (0.5 mL, 3000 Da MWCO). 
Centrifugation was performed at 4,000 X g for 4 x 20 min at room temperature. The final 
sample volume was adjusted to 280 µL with filtrate. 20 μl of D2O was added and loaded 
into a Shigemi tube (5 mm diameter and 8 mm length at the bottom (Shigemi Inc., Tokyo, 
Japan)).  
HSQC spectra (1D and 2D) were obtained on a 600 MHz Bruker NMR spectrometer 
equipped with a cryogenic probe. The spectral width of the 1H and 15N dimensions were 
16.0221 and 32 ppm, respectively. For each spectrum, 2048 points were used for F1 and 
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128 points were used for F2. After being zero filled to 2048 points in both F1 and F2 (without 
linear prediction), data were Fourier transformed with a squared-sine-bell (SSB) window 
function. Topspin was used for data processing and Sparky was used for data analysis. 
The data was acquired with 2D 1H-15N correlation via double INEPT transfer, using 
sensitivity enhancement via an Echo/Antiecho-TPPI gradient selection method. Trim pulses 
were used during INEPT transfer. Decoupling was applied during acquisition. Total 
experimental analysis was performed for 84 h at 15 °C. 
Multi-variable linear regression of NMR values and drug categories were performed 
to evaluate the similarity between Neupogen® and the proposed biosimilar. Drug category 
was regarded as dependent variable, with the proposed biosimilar defined as 1 and 
Neupogen® defined as 0. Two-dimensional NMR parameters (X and Y values, or 1H and 
15N values) were used as independent variables. The regression was executed using Excel 
software, and regression statistics including R Squared, an ANOVA table and estimated 
parameters, were obtained.  
2.3.7 Intact protein analysis  
LC separation was obtained by injecting 1 µg of sample on an 1290 Infinity system 
(Agilent, Santa Clara, CA) with an Poroshell 300SB-C8 column (1 X 75 mm, 5 µm) (Agilent, 
Santa Clara, CA) at a flow rate of 0.2 ml/min. Mobile phase A was 0.1% FA in water, and 
B was 0.1% FA in acetonitrile. The gradient started linearly ramped from 5% to 99% B over 
6 min and was held at 99% B for 0.5 min, then ramped back to 5% B after 0.5 min, and 
held at 99% B for 1 min. MS analysis was conducted on an Agilent 6530 Mass QTOF 
coupled to ESI in positive dual ESI ion mode with a capillary voltage of 3500 V. Intact data 
was acquired over the mass range between 500-5000 m/z. System suitability was assessed 
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by injecting 1 µg of intact mAb mass check standard. (Waters, Milford, MA) Data processing 
was performed with Agilent MassHunter Workstation Software (Version B. 05. 01).  
2.3.8 Size exclusion chromatography 
UPLC analyses were performed on an Acquity UPLC H-class system (Waters, 
Milford, MA) using an Acquity SEC BEH 125Å column (1.7µm, 2.1mm x 100mm, 1K-80K; 
Waters, Milford, MA). UV detection at 215 nm was chosen. The mobile phase was 20 mM 
ammonium bicarbonate (pH 7) with an isocratic flow rate of 0.3 mL/min, run for 10 min. 
Injection volume was 5 µL, and data analysis was performed using Empower 3 software. 
2.3.9 Reverse phase chromatography 
An Acquity UPLC BEH C18 column (1.7 μm, 2.1 mm × 100 mm; Waters, Milford, MA) 
was used with UV detection at 215 nm, with column temperature set at 60°C. Mobile phase 
A was acetonitrile with 0.1% TFA and mobile phase B was water with 0.1% TFA. A linear 
gradient was used, ramping from 25% to 55% mobile phase A over 13 min and then 
ramping from 55% to 75% mobile phase A over 17 min. The column was equilibrated with 
25% A for 10 min between each injection. The injection volume was 5 µL, and data analysis 
was performed using Empower 3 software.  
 Results 
2.4.1 Primary structures and post-translational modifications 
The primary structures of Neupogen® and its proposed biosimilar were determined 
by LC-MS/MS amino acid sequencing following Glu-C digestion. Figure 2-1 shows the total 
peptide coverage for 3 vial lots of biosimilar and Neupogen®. Total peptide coverage was 
100% (175 of 175) in all 6 samples. Figure 2-2 shows the major modifications of filgrastim 
in 3 vial lots of biosimilar and Neupogen® as observed by LC-MS/MS. Oxidation and 
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deamidation were observed mostly at trace levels (<6 %). Peptides containing oxidized or 
deamidated residues are highlighted by red marks in Figure 2-1. Oxidation levels were 
comparable between Neupogen® and the proposed biosimilar while deamidation levels 
were significantly different between the two at Gln12, (4 -7 % deamidation in Neupogen® 
vs. <1 % in the biosimilar). 
 
Figure 2-1 Sequence coverage map of Neupogen® (blue) and biosimilar filgrastim (orange). 
We confirmed 100% sequence coverage and identical amino acid sequence between the two.      
 
Figure 2-2 (A)Oxidation and (B) deamination levels of filgrastim in 3 vial lots of Neupogen® 
and its proposed biosimilar observed in LC-MS/MS. Peptides containing oxidized or deamidated 
residues are highlighted by red marks in Figure 2-1. N = 3; mean ± SD, Student’s t-test, NS: not 
significant, *p<0.05, **p<0.01) M: Methionine, W: Tryptophan, Q: Glutamate  
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Table 2-1 Detailed percentage values for the major modifications of filgrastim in 3 vial lots 
of Neupogen® and its proposed biosimilar observed in LC-MS/MS. 
 
2.4.2 Higher order structure analysis 
A stable higher order structure is essential for a therapeutic protein to be functional [333]. 
To compare higher order structures between Neupogen® and its biosimilar, we performed 
CIU-IM-MS and 1D, 2D-NMR analysis. ESI MS spectra showed highly similar charge state 
distributions with the highest intensity of 8+ charge in both cases. Their 2D-IM-MS plots 
showed comparable spectra patterns without detecting aggregates such as a dimer and 
trimer. (Figure 2-3) Then, their gas phase unfolding dynamics were compared using the 8+ 
charge ions. The ion intensities are represented by the color axis to the right of plots. The 
averaged CIU contour map appeared to be similar with both drugs. On the contour map, 
three distinct CIU features were detected for the +8 charge state. (Figure 2-4) The most 







% PTM observed 
Vial lot biosimilar Vial lot Neupogen® 
Lot 1 Lot 2 Lot 3 Lot 1 Lot 2 Lot 3 
Deamidation 
Glutamine 12 0.89 0.35 0.43 5.69 4.46 7.03 
Glutamine 174 0.00 0.01 0.00 0.19 0.09 0.19 
Oxidation 
Methionine 1 4.61 4.12 4.50 4.23 4.24 4.46 
Tryptophan 59 1.22 1.45 2.07 1.18 1.69 1.35 
Tryptophan 119 0.70 0.63 0.69 0.67 0.76 0.68 
Methionine 122 1.55 1.08 1.53 0.99 1.38 1.16 
Methionine 127 2.94 2.60 4.24 2.83 3.62 3.76 
Methionine 138 1.35 1.14 1.60 1.44 1.58 1.32 
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experiencing unfolding at the lowest trap collision voltage. Two additional unfolded states 
were observed as the trap collision voltage increased, with each CIU transition initiated 
under nearly identical acceleration voltages (around 30 V).  
 
Figure 2-3 Representative 2D IM-MS plots of (A) Neupogen® and (B) biosimilar and ESI 
MS spectra of (C) Neupogen® and (D) biosimilar 
 
1D 1H-NMR spectra revealed high structural similarity between the two products. 
Notably, the amide backbone region did not show any differences between 6 and 9 ppm. 
However, each signal appeared to be highly overlapped. (Figure 2-5). To overcome the 
overlapping, 2D-1H-15N HSQC was carried out at natural abundance levels of 15N to obtain 
H-N correlations. The peaks shown in the spectra (Figure 2-6) were mainly from the 
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backbone amide groups. Trp side-chain N-H groups at 129.5/9.65 ppm and 128.5/9.75 
ppm and Asn/Gln side-chain N-H groups between 110-115 ppm/6.3-7.5 ppm were also 
visible. Amide peaks in the spectra were well-dispersed from 6.3 ppm-9.75 ppm indicating 
a well-folded protein. There were 108 total NMR signal observations. The R squared value 
was 8.80392E-06, which indicates there was no significant linear relationship between 
NMR parameters and drug category, meaning there were no detectable differences 
between these two drugs in terms of their NMR characteristics.  
 
Figure 2-4 Collision-induced unfolding (CIU) fingerprint of (A) Neupogen® and (B) 





2.4.3 Molecular weight distribution 
Intact mass analysis was performed to determine filgrastim’s molecular weight 
(MW). The resulting deconvoluted spectra showed highly similar MW distribution between 
Neupogen® and its proposed biosimilar (Figure 2-7). Multiple peaks were observed in both 
cases with highly similar abundances, which represented the mass of the main peak 
(18799.0 Da), a +21 Da sodium adduct (18820.0 Da), a +39 Da potassium adduct (18838.0 
Da), and a -133 Da N-methionine clipped peak (18666.0 Da).  
 
 
Figure 2-5 Comparison of 1D 1H NMR specta for (A) biosimilar and (B) Neupogen®. Both 
NMR spectra revealed high structural similarity. 
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Figure 2-6 A plot of the overlay of Neupogen® (red) and biosimilar (blue) 600 MHz 2D 1H-
15N NMR spectra at 15°C (1H range: 6.2 to 10 ppm, 15N range 101.7 to 130.3 ppm). Sample 
similarity can be directly assessed by visual comparison of spectral overlays. Resonance are 




Figure 2-7 A representative mirror plot of deconvoluted intact mass between innovator 
(VL158) and biosimilar filgrastim (VL81). (1) N-methionine clipped filgrastim [M-met], (2) filgrastim 
[M], (3) filgrastim+Na adduct [M+Na]- and (4) filgrastim+K adduct [M+K]+. 
 
2.4.4 Variants analysis 
Size exclusion and reversed phase liquid chromatography (SEC-LC and RP-LC) are 
used to detect product-related variants such as high molecular weight (HMW), deamidated 
and oxidized species. Because HMW species (aggregates) can lead to immunogenicity, 
characterization of soluble aggregate content is required for the development of biologics 
and biosimilars. In our study, both drugs showed very low levels of high molecular species 
for all lots, with comparable levels shown. In addition to LC-MS/MS analysis on deamidation 
and oxidation levels, we also performed RP-LC analysis. Oxidized variants elute out earlier 
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than the main filgrastim peak while deamidated variants elute out later. RP-LC data showed 
both low and comparable levels of oxidation (Neupogen®: 0.79 ± 0.18 %, its proposed 
biosimilar: 0.74 ± 0.05 %). In terms of deamidation, both showed highly similar levels at 
1.08 relative retention times (Neupogen®: 0.56 ± 0.24 %, its proposed biosimilar: 0.57 ± 




Figure 2-8 Overlays of SEC-UPLC chromatograms of (A-C) the biosimilar and (D-E) 
Neupogen®. Both showed very low high molecular weight species and fragmented species.  
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Figure 2-9 Overlays of reversed-phase UPLC chromatograms of the innovator and its 
biosimilar. Three biosimilar syringe lots (A-C) were used to show oxidized and deamidated variants 
as compared to Neupogen syringe lots: (D-F) 
 Discussion 
Biosimilar development requires extensive physicochemical characterization as a 
foundation to generate a highly similar biosimilar product. To support a fingerprint-like 
analysis, orthogonal techniques are used to elucidate the complex structure of protein 
drugs. We performed a comparative analysis of Neupogen® and its potential biosimilar 
using LC-MS/MS peptide mapping based multi-attribute method (MAM). The primary amino 
sequence between Neupogen® and the proposed biosimilar appeared to be the identical 
as shown by MS/MS peptide mapping. Glu-C was used to digest filgrastim, cleaving Asp 
or Glu.  
Filgrastim contains 4 Met residues, which are prone to oxidize into sulfoxide 
derivatives. Met oxidation is one example from a broad list of PTMs that can affect a protein 
or peptide’s biological activity. [192] Outside of methionine 1 (non-functional), it has been 
known that oxidation of the other three methionine residues (122, 127 and 138), which are 
located in close proximity and all facing the protein’s interior, are closely related to a 
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decrease of potency. [336,337] Thus, comparison of oxidation levels can be useful for 
identifying the source of discrepancies in potency. In this analysis, oxidation levels were 
comparable between Neupogen® and its proposed biosimilar filgrastim. Methionine 1 
showed the highest level of oxidation, which was expected since the N-terminal Met is the 
most easily accessible of the four residues. [338] To support this data, a further study on 
potency would be helpful. Interestingly, Neupogen® showed significantly higher levels of 
deamidation of glutamine residues 12 and 174. Although deamidation was not related to its 
biological activity, the lower deamidation level is desirable since it is one of the degraded 
products of filgrastim.  
Both proteins had comparable high order structures and MW profiles based on IM-
MS, NMR and intact MS analyses. CIU-IM-MS analysis can be a useful tool to evaluate 
biosimilarity since CIUs have been applied to detect subtle differences such as 
glycosylations and disulfide bonds in innovator IgG drug products and their biosimilars. 
[54,108,339] This is the first time CIU analysis has be used to compare filgrastim 
biosimilarity based on the rationale that proteins of high structural similarity will show almost 
identical unfolding patterns. During the CIU process, both the innovator and biosimilar 
showed the same number of structural features upon the addition of collision energy. The 
CIU patterns in the gas phase between Neupogen® and the biosimilar appeared to be 
comparable regarding feature shapes, drift time and transition values of collision voltage. 
1D-1H NMR analysis provides a fast and simple structural analysis, but showed a highly 
overlapped signal due to the protein’s complex structure and non-selectivity towards 
excipients. This limitation can be overcome by 2D NMR analysis. [340] Recently, 2D-NMR 
analysis for biotherapeutics has been used to provide a comprehensive readout of the drug 
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conformation along the polypeptide chain at an atomic level while providing a higher order 
structural comparison between innovator and biosimilar. [341,342] Intact analysis is used 
to assess characteristics of protein purity and heterogeneity. Based on this, we were able 
to get accurate estimates of filgrastim’s MW. N-terminal Met truncated species were 
detected in both cases, but their presence was not expected to decrease the activity of 
filgrastim since G-CSF also lacks an N-terminal Met. Regarding impurity analyses using LC 
separation, both showed similar oxidation and deamidation levels, however LC-MS/MS 
data showed significantly lower deamidation levels in the biosimilar. This discrepancy is 
due to the different resolution between analysis methods. LC-MS/MS provides site specific 
quantification by showing percent modified of individual amino acid modification with high 
sensitivity, while LC-C18 quantifies relative amount of the entire molecule depending on 
affinity to the column. [344] Also, SEC separation confirmed very low levels of high 
molecular weight species below 0.1 % in both.  
Taken together, we have applied MAM analysis to confirm the identical primary 
structure, similar oxidation and significantly different deamidation level between 
neupogen® and its biosimilar. Although we have only acquired data on amino acid 
modifications such as deamidation and oxidation using MAM, MAM can be used to provide 
a much wider variety of data such as glycosylation, glycation, clips, isomerization and host 
cell protein with biotherapeutics in single assay. Such MAM assay will provide 
comprehensive and timely support for analytical characterization. Also, we have 
demonstrated comparable higher order structure and molecular weight distribution with 
different MS techniques and 2D-NMR. Interestingly, we have confirmed different resolution 
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depending on analytic methods on the same attribute – LC-MS/MS and LC-C18 analysis 
























Chapter 3: Multifaceted Assessment of Rituximab Biosimilarity: The 
Impact of Glycan Microheterogeneity on Fc Function 
 Abstract 
Biosimilars are poised to reduce prices and increase patient access to expensive, 
but highly effective biologic products. However, questions still remain about the degree of 
similarity and scarcity of information on biosimilar products from outside of the US/EU in 
the public domain. Thus, as an independent entity, we performed a comparative analysis 
between the innovator, Rituxan® (manufactured by Genentech/Roche), and a Russian 
rituximab biosimilar, Acellbia® (manufactured by Biocad). We evaluated biosimilarity of 
these two products by a variety of state-of-the-art analytical mass spectrometry techniques, 
including bottom-up protein digestion followed by LC-MS/MS, HX-MS, IM-MS, and intact 
MS. Both were found to be generally similar regarding primary and higher order structure, 
though differences were identified in terms of glycoform distribution levels of C-terminal 
Lys, N-terminal pyroGlu, charge variants and soluble aggregates. Notably, we confirmed 
that the biosimilar had a higher level of afucosylated glycans, resulting in a stronger FcγIIIa 
binding affinity and increased ADCC activity. Taken together, our work provides a 




A biosimilar is a follow-on biologic drug that has highly similar physicochemical 
properties to the innovator product with no clinically meaningful differences in terms of 
safety and efficacy. [305] Recent patent expirations for lucrative biopharmaceutical 
products has led to the regulatory approvals for a number of biosimilars. So far, 45 
biosimilars have been approved by the European Medicines Agency (EMA) and 17 
biosimilars have been approved by the Food and Drug Administration (FDA). Among these 
approved biosimilars, twelve are monoclonal antibody (mAb) based drugs. [324,325] In 
contrast to generic small molecule products, biosimilars are not identical copies of the 
innovator products. Biosimilar mAbs are especially challenging to develop due to their 
structural complexity, including several functional domains, post translational modifications 
(PTMs), and possible immunogenicity. [326,327] The most frequently observed structural 
differences in biosimilar mAbs are in glycosylation profile, charge variants, incorrect 
disulfide bridging, and C-terminal or N-terminal amino acid variations. [53–
55,66,68,226,328,329] In most cases, multiple orthogonal analytical methods are utilized 
to complementarily investigate each quality attribute as there is no single, perfect method 
to reveal biosimilarity as a whole. Biosimilar development for FDA approval requires the 
consideration of a totality-of-evidence and a step-wise approach to demonstrate 
biosimilarity by filling the gaps between residual uncertainty after analytical characterization 
for prediction of clinical similarity. [64,305] 
Rituxan® or MabThera® is the rituximab innovator product developed by 
Genentech/Roche, and was approved by the FDA in 1997. [330] Rituximab is a chimeric 
human/murine mAb against CD20 on the surface of malignant B cells. [331–333] It is 
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administered to treat non-Hodgkin’s lymphoma, chronic lymphocytic leukemia and 
refractory autoimmune disorders. [334–337] One of the main mechanisms of action of 
rituximab is antibody dependent cellular cytotoxicity (ADCC), which results in tumor cell 
lysis. [331–333] Once bound CD20 on the malignant B cell, rituximab’s fragment 
crystallizable (Fc) region binds to the FcγIIIa receptor on effector cells, such as NK cells 
and macrophages, which leads to the degranulation of lytic enzymes, resulting in tumor cell 
death. [338,339] It is known that afucosylated glycoforms show stronger binding affinity to 
the FcγIIIa receptor, resulting in rituximab’s higher ADCC activity. [340–342] Therefore, 
comprehensive glycoform profiling and functional bioassays are important to verify mAb 
biosimilarity. 
Since rituximab’s patent expirations in 2018 (US) and 2013 (Europe), [343] many 
companies have been developing potential rituximab biosimilars. These include Truxima® 
(Celltrion) approved in February 2017 [344] by EMA as the first mAb biosimilar for an 
oncology indication, followed by approval of Rixathon® from Sandoz in June 2017. [345] 
Following initial rejection by FDA of both rituximab biosimilar products, Truxima® was 
eventually approved in November 2018[325], whereas the application for Rixathon® was 
withdrawn. [346] Additionally, multiple rituximab biosimilars have been approved outside of 
the US and EU in India, Latin America and Russia. For example, there are currently five 
rituximab biosimilars available in India, including Maball® (Hetero), RituxiRel® (Reliance) 
and Reditux® (DRL). [347] Similarly, there are currently two approved rituximab biosimilars 
in Russia, AcellBia® (Biocad) and Reditux® (DRL). [348] These differences in rituximab 
biosimilars availability reflect vastly different requirements for biosimilar approvals from 
country to country. 
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Approval of biosimilar products by the FDA/EMA is often accompanied by a 
publication from a biosimilar developer summarizing product analytical comparability data 
used in the regulatory filling. [54,55,66,275] In stark contrast, only limited amounts of 
information is available about the biosimilars approved in countries outside of the EU/US. 
In addition, few publications on biosimilar characterization are authored by the analytical 
laboratories independent from the biosimilar developer. Here, we compare innovator 
rituximab (Rituxan®) and a biosimilar rituximab (AcellBia®) that has been approved in 
Russia, Latin America, and Asia. We utilize orthogonal techniques to evaluate their primary 
sequence, higher order structure, PTMs, including glycosylation patterns, charge variants, 
oxidation, deamidation, FcγRIIIa binding affinity and ADCC activity. We aim to define a 
correlation between structural and functional differences between the innovator and 
biosimilar rituximab drug products, with an enhanced focus on glycosylation and ADCC. 
 Materials and methods 
3.3.1 Materials 
Rituximab biosimilar (Acellbia®) and rituximab innovator (Rituxan®) lots were 
purchased and stored at 4ºC until use. All materials used were before their expiry date. 
3.3.2 Digestion 
Antibody samples (50μg) were digested using AccuMAP™ Low pH protein digestion 
kits (Promega) according to the manufacturer’s protocol. In short, samples were denatured 
with guanidine hydrochloride, reduced with tris(2-carboxyethyl)phosphine, and alkylated 
with iodoacetamide. The samples were predigested with AccuMAP™ Low pH resistant 
rLys-C for 1 hour then digested with AccuMAP™ Modified Trypsin and Accumap™ Low pH 
resistant rLys-c at 37°C for 3 hours. All steps were performed at mildly acidic conditions to 
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suppress artificial deamidation. Finally, the samples were acidified with trifluoroacetic acid 
and purified with a SepPak C18 Plus light cartridge. 
3.3.3 Peptide mapping 
Digested samples (500ng) were analyzed by a Dionex RSLC-nano UHPLC system 
interfaced with a Q Exactive HF mass spectrometer (ThermoFisher). The samples were 
separated by an EASY-spray system PepMap RSLC C18 column (500 mm, 75 μm, particle 
size: 2 μm, pore size: 100Å) (ThermoFisher) using 1% acetic acid / acetonitrile gradients 
at 300 ml/min and introduced into a Q Exactive HF mass spectrometer. Data were collected 
in the range of m/z 600-2000 using Orbitrap for detection. LC-MS/MS data were searched 
by Byonic™ search software and validated by Byologic® (Protein Metrics Inc.). Peptide 
ions were identified using the search software by comparing computed masses to precursor 
peptide masses (MS1) and expected fragment ion masses (MS2), enabling the search of 
various protein modifications such as deamidation, oxidation (mono-, di-), N-terminal 
glutamate to pyroglutamate conversion and an N-glycan. N-glycan species were 
automatically assigned based on a predetermined library of 50 biantennary glycans. 
3.3.4 Ion mobility mass spectrometry 
Innovator and biosimilar were supplied as solution of identical formulations 
(Rituximab, sodium chloride, sodium citrate dihydrate, and polysorbate 80). All samples 
were diluted with pure water to a concentration of 1 mg/mL (~6.7 µM) and then samples 
were buffer exchanged into 200 mM ammonium acetate buffer using Micro Bio-Spin 30 
columns (Bio-Rad).  Antibody aliquots (~7 µL) were analyzed by IM-MS on a quadurople-
ion mobility-time-of-flight mass spectrometer (Q-IM-ToF MS) (Synapt G2 HDMA, Waters). 
Antibody ions were generated using a nESI source in positive ion mode. The electrospray 
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capillary was operated at voltages of 1.5-1.7 kV with the sampling cone operated at 40 V. 
The trap traveling-wave ion guide was pressurized to 4.96 × 10−2 mbar of argon gas. The 
traveling-wave ion mobility separator was operated at a pressure of ∼2.6 mbar. Ion mobility 
separation was achieved with a DC generated wave operated at 40 V wave height traveling 
at 600 m/s. The ToF-MS was operated over the m/z range of 1000−10,000 at a pressure 
of 1.5 × 10−6 mbar. Mass spectra were calibrated externally using a solution of cesium 
iodide (100 mg/mL) and processed with Masslynx V4.1 software (Waters). Exact molecular 
masses of intact antibody samples were calculated by assigning the charge states based 
on the set that gives the lowest standard deviation for a given average mass assignment. 
3.3.5 Collision induced unfolding  
Antibody ions were subjected to collision in the travelling-wave ion trap prior to IM 
separation to perform antibody CIU. Tandem-MS (quadrupole selection) was used to select 
the 23+ charge state of the intact antibody ion. The collision voltage was ramped from 5 to 
200 V in 5 V increments to construct the CIU fingerprints data. Drift time data was extracted 
at each collision voltage in DriftScope (Waters) using TWIMExtract. [349] These extracted 
drift time data were analyzed using a home-built software package, CIUSuite 2. [350] 
CIU “fingerprint” data was plotted as a 2D contour plot such that the intensity was 
normalized between data sets to a maximum value of 1 at each collision voltage and 
smoothed once using a Savitzky-Golay filter. Features in these fingerprints are detected by 
grouping the observed drift times for each collision voltage. The settings for feature 
detection were a minimum of 5 steps, an allowed drift time width of 0.75 ms, and a 
maximum CV gap length of 0 Following feature analysis the CIU50 values were calculated 
by fitting the transition regions between features with a logistic function. We define the 
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CIU50 value as the voltage in which 50% of a relatively compact state transition to a more 
extended state. 
3.3.6 Hydorogen exchange mass spectrometry 
Stock solutions (10 mg/mL) of innovator and biosimilar rituximab were dialyzed with 
10K MWCO Slide-A-Lyzer MINI devices for 20 hours (buffer exchanged at 6 hours) at 4 °C 
in protein buffer (25 mM citrate buffer with 150 mM sodium chloride, pH 6.5).  After dialysis, 
protein concentrations were measured by a Bradford assay and adjusted to 2.4 mg/mL for 
HX experiments. HX experiments were performed on a LEAP Technologies H/X PAL robot. 
Deuterated samples were prepared by diluting 3 μL of mAb (2.4 mg/mL) with 57 μL of 
protein buffer in D2O (25 mM sodium citrate, 150 mM NaCl, pD 6.5). Samples were labeled, 
in triplicate, at 25 °C for 20, 100, 500, 2500, 12500, and 62500 seconds. Labeling was 
quenched at 0 °C by a 1:1 dilution with quench buffer (200 mM phosphate, 3 M guanidine 
hydrochloride, 0.5 M Tris(2-carboxyethyl)phosphine hydrochloride, pH 2.5). Following 
quench, 4.8 μg of sample was injected into the sample loop in a temperature-controlled 
chromatography cabinet at 0 °C connected to an Agilent 1260 infinity series LC. Injected 
sample was passed over an immobilized pepsin column (2.1 mm x 50 mm) prepared in 
house [351] at 200 μL/min for 180 seconds with 0.1% formic acid in water. After digestion 
peptic peptides were captured on a C8 trap (InfinityLab Poroshell 120 EC-C8, 2.1 x 5 mm, 
2.7 µm) and desalted for 60 seconds at 200 μL/min with 0.1% formic acid in water. Peptic 
peptides were then separated on a C-18 column (ZORBAX RRHD 300Å Stable Bond C-
18, 2.1 x 50 mm, 1.8 µm) with a 12 min linear gradient of 0.1% formic acid in acetonitrile 
increasing from 15% to 35%. Peptides masses were measured on an Agilent 6530 
Quadrupole Time-of-Flight mass spectrometer running in ESI-positive mode. Raw HX-MS 
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data was processed in Sierra Analytics HDExaminer and exported to Microsoft Excel for 
post-processing. Relative deuterium uptake is expressed as the peptide mass increase 
divided by the number of peptide backbone amides. When the second residue of the 
peptide is not proline, the number of peptide backbone amides was decreased by one to 
account for rapid back-exchange by the amide adjacent to the N-terminal residue. [352] 
The criterion for significance in individual HX differences was defined by pooled standard 
deviation obtained from the entire collection of 2676 HX differences, 0.032 Da. The pooled 
standard deviation was propagated as random error through an HX difference and 
multiplied by Student’s t for a two-tailed difference at 99% confidence for four degrees of 
freedom, 4.604. This yielded a threshold of significance for individual HX differences of 0.21 
Da. 
3.3.7 Intact mass spectrometry 
Intact mass antibody characterization was performed in 2 different ways; without 
enzyme treatment and deglycosylated. First, each antibody sample (50 μg) was diluted with 
water and exchanged 4 times into a 20% acetonitrile solution containing 1% acetic acid 
using a 10 KDa Nanosep filter (Pall). Protein was recovered from the filter in water and 
concentration determined by a Qubit fluorometer (Invitrogen). For intact mass analysis: 
sample concentration was reduced to 0.5 mg/mL with HPLC grade water. For 
deglycosylated intact mass: 20 μg of antibody was incubated with 3 μL PNGase F 
(Promega) in 50 mM ammonium bicarbonate at 37°C for 3 hr. Samples were analyzed by 
LC-MS using a C4 column (X-Bridge BEH C4 2.1 x 50 mm) (Waters) interfaced to a Q 
Exactive mass spectrometer (ThermoFisher). 500 fmols or 5pmols was injected for intact 
or reduced samples, respectively. Data were acquired from 600-4000 m/z at a resolution 
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of 17,500 FWHM (at 400 m/z) with ten μscans per spectrum (intact mass), or 600-2500 m/z 
at a resolution of 17,500 FWHM (at 400 m/z) with three μscans per spectrum (reduced 
mass). Spectral deconvolution was performed with Intact Mass™ ver 3.3 (Protein Metrics 
Inc.). 
3.3.8 Cation exchange chromatography 
Antibody samples (10 mg/ mL) were filtered with a 0.45 µm filter. 5 µL of samples 
was injected into Waters Alliance HPLC onto a MAbPac SCX-10 column (4 x 150 mm, 5 
µm) (Thermofisher). Mobile phase A was 20 mM MES buffer (pH 5.6) and mobile phase B 
was 20 mM MES buffer with 300 mM NaCl (pH 5.6), ran at flow rate of 1 mL/min at 30°C 
for 20 min using a linear 30-60% B gradient.The signal was detected at 280 nm. To confirm 
C-terminal Lys truncation, samples were incubated with carboxypeptidase B (Worthington 
Biochemical) for 2 hours at 37°C and then analyzed by the cation exchange 
chromatography method above. 
3.3.9 Size exclusion chromatography 
Antibody samples (10 mg/mL) were diluted 2-fold and filtered with a 0.45 µm filter. 5 
µL samples were injected into Waters Alliance HPLC system and separated with a TSKgel 
SuperSW mAb HR column (7.8 mm x 30.0 cm, 4 µm, 25 nm) (Tosoh). 0.2 M phosphate 
buffer (pH 6.7) with 0.05% NaN3 was chosen for the mobile phase, with a flow rate of 0.8 
mL/min. The signal was detected at 280 nm. 
3.3.10 Glycan profiling by fluorescent labelling and LC analysis 
N-glycans were prepared from antibody samples (15 μg) using a GlycoWorks 
RapiFluor-MS N-Glycan kit (Waters) according to the manufacturer’s protocol. Briefly, 
antibody samples were denatured and deglycosylated with PNGase F. Resulting N-glycans 
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were labeled with RapiFluor-MS and cleaned-up with a HILIC microelution plate. Labelled 
N-glycan samples were separated on a UPLC Glycan BEH amide column (2.1 X 150 mm, 
130 Å, 1.7 μm) (Waters) at a flow rate of 0.4 mL/min at 60°C with mobile phase A (50 mM 
ammonium formate pH 4.4) and mobile phase B (acetonitrile) following manufacturer’s 
instructions for gradient preparation.. The signal was detected with a fluorescence detector 
at an excitation wavelength of 265 nm and emission wavelength of 425 nm. 
3.3.11 FcγRIIIa binding assessment by biolayer interferometry  
The interaction of the Fc regions with FcγRIIIa for both innovator and biosimilar 
rituximab were measured by BLI with a BLITZ® instrument (Fortebio), equipped with 
protein G biosensor tips. We followed a previously reported BLI method. [53,353,354] 
Rituximab samples were dialyzed with PBS buffer (50 mM sodium phosphate, 150 mM 
sodium chloride, pH 7.4) and diluted to 0.4 μM with kinetic buffer (PBS buffer containing 1 
mg/mL casein as a blocking agent). Following sample preparation, the protein G biosensor 
tips were loaded (120 sec) with innovator or biosimilar rituximab. A baseline (240 sec) was 
established followed by the association (180 sec) and dissociation (360 sec) of FcγRIIIa, 
as measured by dipping the tips into different concentrations of FcγRIIIa solution and PBS 
kinetic buffer, respectively. After each binding assay, the regeneration procedure was used 
for the biosensor tip, which consisted of two cycles of 30 seconds in 10 mM HCl and 60 
seconds in PBS kinetic buffer. For the determination of the dissociation constant (KD) of 
innovator and biosimilar rituximab, the concentration range of FcγRIIIa was varied by 2-fold 
serial dilutions from 0.4 to 3.2 μM. Data were produced in triplicate and globally fitted to a 
1:1 binding model by BLITZ® pro software (Fortebio) to obtain ka, kd and KD. 
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3.3.12 Antibody-dependent cell-mediated cytotoxicity (ADCC) reporter bioassay 
ADCC Reporter Bioassay (Promega) was used per the manufacturer’s instruction to 
assess ADCC activity. Briefly, the target WIL2-S cells, CD-20 positive human B 
lymphoblastoma cells, were seeded in each well of a 96-well assay plate. After seeding, 
either serially diluted innovator or serially diluted biosimilar rituximab was added to the 
assay plate. As effector cells, either V158 (high affinity FcγRIIIa) or F158 (low affinity 
FcγRIIIa) variant Jurkat T-lymphocyte cells engineered to stably express FcγRIIIa receptors 
were co-cultured with rituximab treated target cells at an effector cell to target cell ratio of 
6:1 for 6 hours at 37 °C in a humidified 5% CO2 incubator. Once bound to the antibody, 
engineered Jurkat T-lymphocyte cells activated gene transcription through the nuclear 
factor of activated T-cells (NFAT) pathway, inducing the expression of firefly luciferase. 
Lastly, luciferase activity was quantified using luciferase assay reagent by a SpectraMax 
M3 plate reader (Molecular Devices). 
 Results 
3.4.1 Primary structure 
According to FDA and EMA regulations, the primary sequence of the biosimilar 
should be identical to the innovator. [13,64] To confirm the identical sequence between the 
innovator and biosimilar, protein digestion and pre-digestion steps were performed with 
trypsin/Lys-C at mild acidic conditions. This procedure was completed at mildly acidic 
conditions to suppress any artificial non-enzymatic protein modifications commonly induced 
during peptide mapping sample preparation. Base peak chromatograms generated post 
digestion were shown in Figure 3-1. Both innovator and biosimilar had identical sequence 
with 100% coverage. The presence of N-terminal pyroGlu, oxidation and deamidation 
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products were observed for both the biosimilar and the innovator as discussed in detail later 
in the manuscript. 
3.4.2 Higher order structure 
Appropriate higher order structure (HOS) is crucial for proteins to ensure proper 
biological activity. [355] Thus, HOS should be thoroughly evaluated by orthogonal methods 
to reveal potential differences. To evaluate the HOS of innovator and biosimilar rituxmabs, 
we performed a mass spectrometry (MS) based analysis using ion mobility MS (IM-MS) 
and hydrogen exchange MS (HX-MS).  
Collision induced unfolding (CIU) fingerprints acquired by IM-MS have recently 
emerged as a powerful method to differentiate higher order structural information for intact 
mAbs. [53,99,102,356] CIU fingerprints are generated by increasing the internal 
temperature of antibody protein ions in a stepwise fashion through collisions with a 
background gas, resulting in unfolding that is then followed by IM separation and MS 
analysis. CIU fingerprint plots track the amount of applied collision voltage used to generate 
the observed protein ion unfolding transitions. Previous CIU fingerprint analysis of mAbs 
have distinguished unique conformational features including: antibody subclass, 
glycosylation states, antigen binding potential, domain exchange, and biosimilarity. 
biosimilarity. [53,99,102,357] 
The 23+ charge state for both the innovator and biosimilar was chosen based on its 
relative intensity (Figure 3-2A and D), and ability to provide CIU fingerprints containing a 
suitable number of transitions for high-confidence mAb analysis. Three prominent CIU 
features were detected for both the innovator and biosimilar, including an initial, compact 
state and 2 unfolded states (Figure 3-2B and E). Median drift times values for each feature 
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were determined to be near identical between the innovator and biosimilar suggesting 
similar collision cross sections (Figure 3-3A). 
 





Figure 3-2 Ion mobility mass spectrometry of (A) innovator and (D) biosimilar. Average CIU 
fingerprints of (B) innovator and (E) biosimilar rituximab. Standard deviation of rituximab (C) 
innovator and (F) biosimilar. (n = 3) 1: initial compact state, 2,3: unfolded states. 
 
The CIU fingerprints were further analyzed using sigmoidal fitting to determine 
CIU50 values, the collision voltages where the most intense feature decreases to below 
50% of the relative intensity of its neighboring feature, for each mAb. While the initial 
transitions occurred at nearly identical collision voltages (CIU501) of 69.8 V, there were 
noticeable differences between the CIU50 values recorded for the second transitions 
(CIU502), specifically 148.7 V and 143.7 V, for the innovator and biosimilar respectively 
(Figure 3-3 and 3-4). We also detected subtle differences in the standard deviations 
between CIU replicates recorded for innovator and biosimilar 23+ ions at collision voltages 
greater than 150 V (Figure 3-2C and F). 
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Figure 3-3 Median drift times for (A) innovator and (C) biosimilar rituximab. CIU50 values 
between dominant features (between initial compact state and the next unfolded state, between 










Figure 3-4 CIU50 values of innovator and biosimilar at transition 1 and 2. (***p<0.001, 
student t test) 
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The conformational dynamics of the innovator and biosimilar rituximab were further 
compared by HX-MS. The rate of protein backbone amide hydrogen exchange with solvent 
deuterium is dependent on backbone structure and dynamics. [358] Flexible regions of the 
protein exchange rapidly while rigid regions exchange slowly. After exchange, peptic 
digestion followed by MS analysis provides a peptide resolution of hydrogen exchange 
kinetics, providing information on localized protein backbone conformational dynamics that 
can serve as a probe for higher order structure comparability. [359] 
HX profiles, illustrated as a butterfly plot (Figure 3-5), are highly symmetrical when 
comparing average HX measurements across six labeling times for innovator and 
biosimilar rituximab. Relative deuterium uptake is plotted on the vertical axis for each label 
time of each peptic peptide monitored on the horizontal axis. HX was monitored for 223, 
MS/MS confirmed, peptic peptides giving 98.8% total sequence coverage. Peptides 
containing G0F, G1F, and G2F at heavy chain (HC) Asn 301 as well as pyroGlu at HC and 
light chain (LC) Gln 1 were monitored for both innovator and biosimilar rituximab. Deuterium 
uptake at each label time for each peptide was compared between the innovator and 
biosimilar rituximab. All deuterium uptake differences were less than 0.19 Da and none 
exceeded the significance limit of 0.21 Da (Figure 3-6). Thus, there were no significant 
differences when comparing HX of innovator to biosimilar rituximab.  
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Figure 3-5 HDX-MS butterfly plot comparing innovator (top) and biosimilar (bottom) 
rituximab average relative deuterium uptake for each peptic peptide monitored from labeling times 
of 20 (blue), 100 (red), 500 (green), 2500 (purple), 12500 (light purple), and 62500 (grey) seconds. 










Figure 3-6 Deuterium uptake difference (Biosimilar – Innovator) at each label time for each 
peptide. Significance line at 0.21 Da representative of 99% confidence level from pooling 2,676 
experimental standard deviations from all peptides and label times measured. #DiRB was 
subtracted from #DiRO, anything in the positive direction (faster exchange) would suggest RB is 
more flexible relative to RO and anything in the negative direction (slower exchange) would suggest 
RB is less flexible relative to RO. 







3.4.3 Intact antibody mass analysis 
Intact mass spectrometry provides a rapid assessment of the potential differences 
between innovator and biosimilar mAbs, including the presence of low molecular weight 
impurities, covalent aggregates, N-terminal/C-terminal modifications and relative glycoform 
distributions. We performed intact mass analyses of the two products in both their fully 
glycosylated and deglycosylated (Figure 3-7). Expected major intact mass modifications 
are altered glycosylation patterns, N-terminal conversion of Gln to pyroGlu (-17 Da mass 
difference) and absence of C-terminal Lys (-128 Da mass difference). [163] Peak 
assignments were obtained by mass calculations of amino acid sequences and various 
glycan compositions. 
First, the intact masses of innovator and biosimilar rituximab were acquired in their 
fully glycosylated state. The three most abundant charge states were z = 52, 53 and 54 in 
both cases. The glycoform distributions analyzed from the deconvoluted spectra for the 
biosimilar and innovator are shown as a mirror plot in Figure 3-7A. In both cases, the most 
abundant glycoforms were G0F/G0F, G0F/G1F and G0F/G2F or (G1F)2. A Man5/Man5 
peak was detected with a relative intensity of 5%, but only for innovator rituximab. The most 
significant difference detected was the mass peaks containing one C-terminal Lys found in 
the biosimilar, relative to innovator. These peaks are marked with red asterisks in Figure 3-
7A and exhibit mass differences of approximately +128 Da from the more prominent (-)Lys 
peaks. 
To further characterize structural modifications of biosimilar and innovator rituximab, 
mAbs were deglycosylated by PNGase F. When deglycosylated, two main peaks were 
detected from the deconvoluted intact mass analysis (Figure 3-7B) that are likely attributed 
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to an N-terminal 4 pyroGlu and/or glycation (+161 Da). The presence of a peak containing 
one C-terminal Lys was observed for the biosimilar, but not for the innovator. 
 
Figure 3-7 (A) Mirror plot of deconvoluted intact mass spectrum of innovator and biosimilar 
rituximab. (B) Mirror plot of deconvoluted intact mass spectrum of deglycosylated innovator and 
biosimilar rituximab. 
 
3.4.4 Amino acid modification 
Multiple attribute analyses (MAM) allows us to evaluate a variety of protein PTMs in 
a single mass spectrometry assay by computationally analyzing mass data following a 
enzymatic digest of the biosimilar and innovator pair. [53,318] The MAM analysis of 
Rituxan® and Acellbia® is shown in Figure 3-8A, B and C, and Table 3-1 with statistically 
significant differences in oxidation, deamidation and pyroGlu levels determined by a 
Student’s t test. The levels of single amino acid oxidation were comparable except Trp 47 
oxidation which was higher for the innovator at 0.23 ± 0.1% relative to 0.2 ± 0.0% for the 
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biosimilar (p < 0.05). In addition, deamidation levels of Asp 55 on HC as well as Asp 136 
on LC were significantly higher for the biosimilar product relative to the innovator. Due to 
the presence of N-terminal Gln, rituximab has tendency towards the formation of cyclized 
Glu. [329] We found different levels of the N-terminal Glu to pyroGlu conversion (Figure 3-
8C). Percentage of N-terminal pyroGlu conversion on HC was 98.8 ± 0.1% for the biosimilar 
and 98.5 ± 0.1% for the innovator (p < 0.05), while the levels of N-terminal pyroGlu 
conversion on LC was only 58.1 ± 1.0% for the biosimilar and 81.2 ± 6.4% for the innovator 
(p < 0.01). 
 
Figure 3-8 LC-MS/MS analysis of tryptic digested rituximab biosimilar and innovator: levels 
of (A) oxidation, (B) deamidation, and (C) formation of N-terminal pyro glutamic acid. M: Methionine, 
W: Tryptophan, H: Histidine, N: Asparagine Q: Glutamine, HC: Heavy chain, LC: Light chain (N = 







3.4.5 Charge and size variant profiles 
Cation exchange (CEX) chromatography separates molecules using a negatively 
charged ion exchange resin that interacts with positively charged molecules on the surface. 
MAbs are prone to have charge variants resulting from PTMs, including the presence of C-
terminal Lys, N-terminal pyroGlu and deamidation, which could potentially affect their 
quality, safety and efficacy. [190,360] As shown in Figure 3-9A, both biosimilar and 
innovator rituximab exhibited three distinct variant groups: main peak, acidic variants and 
basic variants containing one or two C-terminal Lys. The sums of the innovator and 
biosimilar acidic variants were 17.0 ± 0.1% and 21.3 ± 0.5%, respectively. The slight 
difference between the sums of the acidic variants was attributed to common sources of 
acidic variants such as sialylation and deamidation. [190] However, unlike the acidic 
variants, significant differences were observed in the basic charged variant patterns for two 
rituximab products. The sum of basic variants was calculated as 6.0 ± 0.2% for the 
innovator and 27.7 ± 0.3% for the biosimilar. To examine if the basic variants in the 
biosimilar correspond to the presence of C-terminal Lys, biosimilar samples were treated 
with carboxypeptidase B (CPB) and reanalyzed by CEX. The percentage of basic variants 
of biosimilar decreased to 9.8 ± 0.2% following CPB treatment (Figure 3-10), confirming 
the presence of C-terminal Lys in Acellbia®, which is in line with the intact mass results. 
Protein aggregation the primary stability concern for biopharmaceutical products. 
[76] The presence of aggregates could impact protein efficacy and safety as the presence 
of aggregates could lead to increased product immunogenicity. [252] Size variants for 
innovator and biosimilar rituximabs were determined by size exclusion chromatography, 
separating molecules by size difference as a function of their diffusivity into a porous matrix 
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of resin particles. As seen in Figure 3-9B, the biosimilar showed higher levels of 
dimerization (3.0 ± 0.0%) compared to the innovator (0.5 ± 0.2%).   
 
Figure 3-9 (A) Representative charge variant profile and (B) representative size exclusion 
Chromatogram of rituximab biosimilar and innovator. 
 
 
Figure 3-10 (A) Representative charge variant profiles of the innovator and biosimilar 
rituximab with or without carboxypeptidase B (CPB) treatment. 
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3.4.6 Glycoform distribution 
Glycosylation affects mAb’s effector functions and pharmacokinetic profile. [340] 
Therefore, understanding the differences in glycan distribution between a biosimilar and its 
innovator is crucial for filling the gap between its analytical residual uncertainty and clinical 
efficacy. Specifically in the context of tumor targeting, different glycoforms lead to variable 
binding affinities between the Fc region and FcγIIIa receptor, resulting in different ADCC 
activity. [361] We analyzed the glycan profiles of the biosimilar and innovator rituximab 
using two different methods; liquid chromatography analysis following fluorescent glycan 
labeling (LC-FLR) and quantitative bottom-up protein digestion followed by LC-MS/MS  
MAM analysis (Figure 3-11, 3-12, 3-13 and Table 3-2, 3-3). With both methods, the most 
abundant glycoforms appeared to be the same in the biosimilar innovator, including G0F, 
G1F and G2F fucosylated biantennary glycans (Figure 3-12A, 3-13A).  
However, some differences in glycoform distributions were detected. A total of 32 
glycoforms were detected by LC-MS/MS, while only 13 glycoforms were detected by our 
LC-FLR methodology. Among these glycoforms, there were 16 afucosylated glycans 
detected by LC-MS/MS compared to 4 detected by LC-FLR. This difference is mainly due 
to the presence of HM glycans. While HM glycoforms were not detected by our LC-FLR 
method, 5 of top 10 most abundant glycoforms were HM glycans as detected by LC-
MS/MS. For LC-FLR method, percentage of afucosylated glycan for the biosimilar and 
innovator were 4.5 ± 0.1 % and 2.0 ± 0.3 %, respectively (p < 0.001). For LC-MS/MS 
method, percentage of afucosylated glycan for the biosimilar and innovator were 8.8 ± 0.1 
% and 4.0 ± 0.1 %, respectively (p < 0.0001) (Figure 3-12B, 3-13B). For both methods, 
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biosimilar rituximab showed double the amount of afucosylated glycans, although the 
absolute afucosylation levels were the method-dependent.  
 
Figure 3-11 N-glycan profiles of rituximab (A) innovator and (B) biosimilar by fluorescence 
LC analysis. 
 
3.4.7 FcγRIIIa binding affinity 
Bio-layer interferometry (BLI) is an optical analytical technique that measures the 
interference pattern prior to and following the interaction between two biomolecules. [362] 
We chose V158 polymorph FcγRIII variants for this analysis that have been shown to 
exhibit a higher affinity to rituximab’s Fc region. FcγRIIIa is an essential mAb mechanism 
of action (MOA), especially where immune-mediated cell killing mechanisms such as 
ADCC, are involved. Based on biosimilar rituximab’s higher afucosylation level, the 
biosimilar was expected to have a stronger FcγRIIIa binding affinity than the innovator.  
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Figure 3-12 (A) N-glycan quantification by fluorescence LC analysis and (B) total 
percentage of afucosylated glycans. (N = 3; mean ± SD, Student’s t-test, *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001) 
 
Figure 3-13 (A) N-glycan quantification by LC-MS/MS, (B) total percentage of afucosylated 





Figure 3-14 Representative BLI sensograms to FcγIIIa receptors of rituximab (B) innovator 
and (C) biosimilar. (N = 3; mean ± (RSD)) 
 
Correspondingly, biosimilar rituximab showed a lower mean KD value (868 ± 203 nM) than 
innovator rituximab (1264 ± 342 nM) as measured by BLI (Figure 3-14). 
3.4.8 ADCC activity 
ADCC is the critical MOA of anti-cancer mAbs, where antibodies recruit FcγR-
bearing effector cells to target “diseased” cells for destruction. To evaluate ADCC activity 
of rituximab, we used WIL2-S target cells, a CD-20 positive human B lymphoblastoma cell, 
and Jurkat effector cells, T lymphocyte cells that stably express either the V158 (high Fc 
affinity) or F158 (low Fc affinity) FcγRIIIa variants. The simultaneous binding of mAbs with 
both target (WIL2-S) and effector (Jurkat) cells leads to the induction of measurable nuclear 
factor of activated T-cells (NFAT) luciferase fluorescence. Biosimilar rituximab exhibited 
higher ADCC activity (Figure 3-15) as a measurement of potency for both V158 and F158 
 85 
FcγRIIIa variants. In the presence of the V158 variant, the half maximal effective 
concentrations (EC50) indicated a significantly higher potency for the biosimilar (1.1 x 10-8 
g/mL) than the innovator (2.1 x 10-8 g/mL) (P < 0.001). Likewise, in the presence of the 
F158 (low Fc affinity) variant, the EC50 values indicated a higher potency for the biosimiliar 
(5.2 x 10-8 g/mL) than the innovator (6.9 x 10-8 g/mL). Statistical differences were compared 
with a two-tailed Student’s t test. Taken together, the biosimilar’s higher afucosylated 
glycan levels resulted in stronger FcγRIIIa binding affinity and higher ADCC activity. 
 
Figure 3-15 Results of ADCC Reporter bioassay of rituximab innovator and biosimilar to 
(A)V variant (high affinity FcγRIIIa) and (B) F variant (low affinity FcγRIIIa) Statistical comparison 
using two-tailed Student’s t test of (C) V variants and (D) F variants. (N = 3; ***p < 0.001) 
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 Discussion  
Even with the patent expirations of many top-selling mAb based drugs, the approval 
of their respective mAb biosimilars has been limited by the lack of a concrete answer to the 
question, “How similar is similar enough?” To answer the similarity question and hasten the 
biosimilar approval process, it is necessary to devise an acceptable list and range of 
relevant critical quality attributes, highlighting differences between innovator and biosimilar 
products. [42,76,305] In our efforts to devise this list, we characterized and compared the 
underlying differences between Acellbia® and Rituxan® in primary structure, PTMs, and 
HOS using various MS-based techniques. We sought to find a relationship between 
structural differences and mAb functional activity, with an enhanced focus on glycosylation 
differences and their relationship with ADCC. Additionally, we compared innovator-
biosimilar rituximab’s numerical differences detected in our study with similar numerical 
differences reported for other EU/FDA approved innovator-biosimilar pairs.  
For our initial characterization, the primary structures of Acellbia® and Rituxan® 
were elucidated by performing bottom-up protein digestion followed by LC-MS/MS analysis. 
LC-MS/MS revealed comparable oxidation and deamidation levels for the two products but 
lower N-terminal pyroGlu formation levels for (58.1% vs 81.2%). In a similar study, lower 
N-terminal pyroGlu levels (95.7%) were observed for Truxima®, an EU/US approved 
rituximab biosimilar, when compared with its rituximab innovator (97.6 %). [363] However, 
it has been previously been shown that differences in pyroGlu formation have no effect on 
mAb HOS, potency and in vivo clearance, indicating limited clinical relevance. 
[191,193,363]  
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We then investigated the impact of primary structure differences (deamidation, 
oxidation and glycosylation) on HOS. [176,364–366] We confirmed that similar primary 
structures corresponded to comparable HOS by IM-MS and HX-MS. Recent studies have 
reported that IM-MS can provide a rapid characterization of mAb disulfide bonding and 
glycosylation states. [53,99,318] By focusing on CIU50 values in our analysis, we minimize 
the influence of overall signal intensity and focus on mAb stability shifts. It has been 
previously observed that mAb glycosylation can affect observed CIU50 values. [99] Thus, 
we rationalize the observed difference in the second CIU50 is related to glycosylation profile 
differences we detect between the innovator and biosimilar. The similarities in CIU 
fingerprint features, standard deviation, median feature drift time, and CIU50 values 
indicate that the biosimilar is comparable to the innovator rituximab. 
Previous HX-MS studies have characterized the impact of PTMs on IgG1’s localized 
structure. [367,368] Recently, More et al. revealed by HX-MS that the conformational 
integrity of the CH2 and CH3 domains are sensitive to different glycoforms. [369] In knowing 
this, we conducted HX-MS experiments and determined that there was an absence of 
significant differences in localized HX-MS conformational dynamics. These results 
supported the previously mentioned structural similarity determined by IM-MS. However, it 
is important to note that structural perturbations due to primary sequence modifications are 
likely below the limit of detection for HX-MS and, therefore, may still be present. We also 
measured any impact on the higher order structure of size variants by HX-MS and detected 
a presence of less than 2.5% for the variants. Taken together, the peptide level resolution 
of HX-MS combined with HOS level analysis by IM-MS seems to provide the confidence to 
support a complete analytical assessment of innovator and biosimilar mAbs. 
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Additionally, the macroscopic characterization and comparison of biosimilar and 
innovator rituximab was performed by intact MS, CEX and SEC analysis. Previous 
biosimilar studies have revealed differences in charge variants derived from the 
presence/absence of C-terminal Lys.[55,66] For example, Mvasi®, an EU/US approved 
bevacizumab biosimilar, showed higher levels of basic variants (8.6%) when compared to 
its innovator (6.1%). This was caused by unprocessed HC C-terminal Lys present in the 
biosimilar. In contrast, Inflectra®, an EU/US approved infliximab biosimilar lacking HC C-
terminal Lys, showed lower levels of basic variants (41.5%) than its innovator (46.2%). 
[55,66,194,275,301]  
In our study, the biosimilar was found to have higher levels of both acidic and basic 
variants, with basic variants corresponding to the presence of C-terminal Lys. This was 
confirmed by CPB treatment and intact MS. However, it has been previously shown that 
the rapid C-terminal Lys clipping upon IV administration is unlikely to alter potency or safety 
nor impact ADCC activity.[55,370] We also found significantly increased levels of high 
molecular weight aggregates in Acellbia® (3.0%) relative to Rituxan® (0.5%). Our results 
reflected those from a recent study on Inflectra® which revealed a relatively higher amount 
of high molecular weight aggregates for the biosimilar (0.8%) when compared to its 
innovator (0.2%). We note, however, that this difference in aggregates did not affect clinical 
immunogenicity for Inflectra®.[54,55] In AcellBia®, the clinical relevance of the effect of the 
higher amounts of aggregate on immunogenicity still needs to be assessed.  
Lastly, we investigated the impact of different levels of afucosylated glycans on 
FcγRIIIa binding affinity and ADCC activity between the biosimilar and innovator rituximab. 
In some biosimilar documents, glycoform analysis was considered as moderate to low (tier 
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2 or 3) in terms of its potential impact on biological activity, safety or immunogenicity. 
[96,301,371] However, several studies have reported a positive relationship between 
afucosylated glycan levels, FcγRIIIa binding affinity and ADCC activity. [328,363,372–375] 
For example, the levels of afucosylated glycans appeared to be approximately ~ 1.5-fold 
higher for the anti-TNF-α innovator Remicade® than its biosimilar Remsima® (10.0% vs 
6.2% as determined by LC-FLR and 19.7 vs 13.2% as determined by LC-MS/MS). This 
difference is reflected in an approximately 2-fold higher FcγRIIIa binding affinity and ADCC 
activity for Remicade® than for Remsima®. In a clinical setting, the difference in FcγRIIIa 
binding affinity and ADCC activity appear to alter the responsiveness of Crohn’s disease 
patients to Remsima® vs. Remicade®. [53,328,376]  
The relationship between afucosylation, FcγRIIIa binding affinity and ADCC activity 
is even more critical for cancer mAb therapeutics where ADCC is the drug’s primary MOA. 
In our study, both LC-FLR and LC-MS/MS methods revealed that the biosimilar contained 
a higher percentage of afucosylated glycans. Differences in the number of detected glycans 
were method-dependent in a similar manner to previous Remicade®/Remsima® 
comparison reports. [53,328] These differences may reflect the necessity of orthogonal 
methods to thoroughly analyze glycoform distributions without overlooking certain species. 
Our results confirmed that higher levels of afucosylated glycans in AcellBia® 
resulted in enhanced FcγRIIIa binding affinity and increased ADCC activity when compared 
with the innovator rituximab. Specifically, twice as many afucosylated glycans were 
observed for AcellBia® relative to Rituxan® (4.5% vs 2.0% detected by LC-FLR method 
and 8.8% vs 4.0% detected by LC-MS). This difference in afucosylation corresponded to a 
2.5-fold difference in EC50 ADCC value (3.7 x 10-9 g/mL for AcellBia® vs 9.2 x 10-9 g/mL for 
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Rituxan®) in presence of effector cells containing a high affinity (V) FcγRIIIa variant. Higher 
levels of afucosylated glycans for Truxima® relative to Rituxan® were also reported by 
Celltrion (3.8 % vs 2.8 % measured by LC-FLR). However, these differences did not result 
in higher ADCC when measured using PBMC effector cells. In the case of Truxima®, the 
numeric difference in afucosylated glycans levels relative to Rituxan® was smaller than 
those found for AcellBia®/Rituxan® and Remicade®/Remsima® pairs. In addition, Celltrion 
has shown an excellent correlation between afucosylation levels and FcγRIIIa (V variant) 
binding/ADCC over a range of 5-50% rituximab afucosylation. Only a limited correlation 
was observed at afucosylation levels below 5%, which is likely due to the assay’s low 
sensitivity. [363]  
Moving forward, it will be critical to examine if the higher ADCC for AcellBia® will 
result in better efficacy for the biosimilar relative to the innovator, especially in patients with 
the V/V polymorph of the FCGR3A gene showing higher binding affinity to therapeutic 
mAb’s Fc portion. In summary, additional research into the relative differences in 
afucosylation, ADCC and clinical activities between multiple biosimilar-innovator pairs is 









Table 3-1 Levels of oxidation, deamidation and pyroGlu of Rituxan® and Acellbia®. 
  Oxidation 
  Rituxan® Acellbia® 




M34 2.74 0.27 2.48 0.36 
M81 0.74 0.43 0.51 0.33 
M256 4.13 0.53 4.28 0.32 
M432 3.89 0.35 3.81 0.44 
W47 0.26 0.05 0.15 0.03 
W106 1.30 0.37 1.69 0.84 
W281 0.53 0.00 0.51 0.08 
W317 0.35 0.10 0.33 0.14 
W385 0.30 0.01 0.23 0.07 
W421 0.56 0.08 0.57 0.05 
H228 0.32 0.09 0.29 0.08 




M21 1.00 0.14 1.09 0.28 
W34 1.38 0.18 1.25 0.06 
W90 1.02 0.02 0.99 0.08 
H197 0.16 0.05 0.14 0.04 
  Deamidation 
  Rituxan® Acellbia® 




N55 0.98 0.20 0.53 0.04 
N290 0.41 0.05 0.35 0.02 
N319 0.17 0.03 0.21 0.01 
N365 0.37 0.03 0.37 0.07 
N394 1.67 0.23 1.68 0.10 
N425 1.29 0.10 1.37 0.21 




N136 0.34 0.03 0.23 0.00 
N157 1.12 0.23 1.17 0.20 
Q1 0.70 0.12 0.62 0.16 
Q88 0.30 0.07 0.40 0.09 
Q198 0.43 0.02 0.43 0.07 
  PyroGlu 
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  Rituxan® Acellbia® 
 Modification site Average (%) Stdev (%) Average (%) Stdev (%) 
Rituximab 
heavy chain 
Q1 98.82 0.13 98.54 0.10 
Rituximab 
Light chain 
Q1 81.20 6.39 58.11 0.97 
 
Table 3-2 Glycoform profiles for Rituxan® and Acellbia® by LC-FLR. 
Glycan Rituxan® Acellbia® 
 Average (%) Stdev(%) Average (%) Stdev (%) 
G0 1.04 0.04 1.18 0.04 
G0F 39.9 0.59 39.10 0.30 
G0FB 2.12 0.02 4.56 0.07 
G1 0.14 0.01 0.22 0.03 
G1F 33.10 0.07 31.29 0.13 
G1F 11.52 0.30 10.39 0.08 
G1FB 0.53 0.02 0.66 0.02 
G2 0.53 0.07 2.87 0.02 
G2F 9.75 0.35 6.83 0.06 
G2FB 0.24 0.27 0.95 0.01 
G1FS1 0.00 0.00 0.48 0.08 
G2S1 0.32 0.24 0.22 0.04 
G2FS1 0.10 0.06 0.26 0.02 
G2FBS1 0.71 0.06 0.99 0.04 
Total 100.00  100.00  








Table 3-3 Glycoform profiles for Rituxan® and Acellbia® by LC-MS/MS. 
Glycan composition Glycan Rituxan® Acellbia® 








HexNAc(1) - 0.04 0.00 0.07 0.01 
HexNAc(2)Hex(4) Man4 0.00 0.00 0.00 0.00 
HexNAc(2)Hex(4)Fuc(1) Man4F 0.09 0.01 0.04 0.00 
HexNAc(2)Hex(5) Man5 1.35 0.07 2.91 0.05 
HexNAc(2)Hex(6) Man6 0.31 0.00 1.69 0.07 
HexNAc(2)Hex(7) Man7 0.08 0.00 0.71 0.03 
HexNAc(2)Hex(8) Man8 0.10 0.01 0.48 0.05 
HexNAc(2)Hex(9) Man9 0.00 0.00 0.02 0.00 
HexNAc(3)Hex(3) G0-GN 0.17 0.02 0.21 0.04 
HexNAc(3)Hex(3)Fuc(1) G0F-GN 0.79 0.08 1.28 0.16 
HexNAc(3)Hex(4) G1-GN 0.02 0.00 0.06 0.00 
HexNAc(3)Hex(4)Fuc(1) G1F-GN 0.68 0.02 1.29 0.05 
HexNAc(3)Hex(5) Man5-GN 0.13 0.01 0.22 0.01 
HexNAc(3)Hex(6) Man6-GN 0.03 0.00 0.14 0.06 
HexNAc(4)Hex(3) G0 0.96 0.09 1.06 0.09 
HexNAc(4)Hex(3)Fuc(1) G0F 41.19 0.95 38.49 1.99 
HexNAc(4)Hex(4) G1 0.66 0.02 0.97 0.01 
HexNAc(4)Hex(4)Fuc(1) G1F 42.49 0.41 40.96 1.21 
HexNAc(4)Hex(5) G2 0.09 0.02 0.11 0.01 
HexNAc(4)Hex(5)Fuc(0)NeuAc(1) G2S1 0.00 0.00 0.00 0.00 
HexNAc(4)Hex(5)Fuc(1) G2F 9.50 0.50 7.61 0.66 
HexNAc(4)Hex(5)Fuc(1)NeuAc(1) G2FS1 0.65 0.16 0.69 0.05 
HexNAc(4)Hex(5)Fuc(1)NeuAc(1)NeuGc(1) G2FS1N1 0.00 0.00 0.00 0.00 
HexNAc(4)Hex(5)Fuc(1)NeuAc(2) G2FS2 0.36 0.03 0.56 0.15 
HexNAc(4)Hex(5)Fuc(1)NeuGc(1) G2FS1 0.00 0.00 0.01 0.00 
HexNAc(4)Hex(6)Fuc(1) G2FGal1 0.03 0.00 0.01 0.00 
HexNAc(4)Hex(6)Fuc(1)NeuAc(1) G2FS1Gal1 0.00 0.00 0.00 0.00 
HexNAc(4)Hex(7)Fuc(1) G2FGal2 0.00 0.01 0.00 0.01 
HexNAc(5)Hex(4) G1B 0.00 0.00 0.13 0.03 
HexNAc(5)Hex(4)Fuc(1) G1FB 0.01 0.01 0.26 0.03 
HexNAc(5)Hex(5)Fuc(1) G2FB 0.00 0.00 0.01 0.00 
HexNAc(5)Hex(5)Fuc(1)NeuAc(2) G2FBS2 0.01 0.00 0.00 0.00 
 Total 100.00  100.00  
 Afucosylated 4.04 0.14 8.78 0.14 
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Chapter 4: Assessment of Biosimilarity Using Forced Degradation: Rituximab, 
Bevacizumab and Trastuzumab Originators and Biosimilars 
 Abstract 
Biosimilars are highly similar to, but not identical with, their originator products. As 
a result, structural differences between originators and biosimilars can be difficult to 
detect and characterize without the appropriate analytical tools. Therefore, we first focus 
on identifying initial structural differences between rituximab, bevacizumab, and 
trastuzumab originator and biosimilar pairs and later address how these differences 
change after applying thermal stress at 40ºC with orbital shaking for 4 weeks. Prior to 
incubation, we detected comparable secondary and tertiary structures for each pair and 
identified different levels of soluble aggregates, charge variants, and molecular weight 
variants due to differences in glycoforms and the number of C-terminal lysines. Over the 
course of incubation, we detected differences in charge variants and unfolding patterns. 
Taken together, our study provides a comparability exercise, providing information on the 
minor differences present between originator and biosimilar products and how those 
differences are impacted by stress.   
 Introduction 
The development of biosimilars, especially monoclonal antibodies (mAbs), is now 
on the rise due to the patent expiry of many lucrative biologic drugs. As of now, 20 
biosimilars have been approved by U.S. Food and Drug Administration (FDA), 13 of which 
are mAbs [377]. Unlike generic small molecule drugs, there may be minor structural 
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discrepancies between biosimilars and their originator drug products due to differences 
in cell line as well as manufacturing and storage conditions. Even when the same cell line 
and manufacturing processes are used, variations in post-translational modifications 
(PTMs) can contribute significantly to functional and structural differences between a 
reference product and proposed biosimilar. [378] Various studies have reported different 
levels of PTMs, including oxidation, deamidation, charge variants, size variants, 
glycosylation, glycation and incorrect disulfide bond formation, between originator and 
biosimilar mAbs. [53–55,226,227,270,275,379,380] In addition, some biosimilars are not 
formulated with the same excipients and buffer system as the originator product. [381–
385] Together, all of these factors make up the potential sources of variability between 
originators and biosimilars. 
For any biosimilar development program, it is pivotal to perform extensive 
biophysical characterization with robust methodologies in order to detect structural 
differences between the reference product and proposed biosimilar. Additional structural 
information can be obtained by subjecting each product to different stresses in attempt to 
exacerbate existing differences while simultaneously providing a product stability profile. 
Forced degradation studies typically use stress conditions such as pH, temperature, light 
and agitation. [300] This is commonly used in industry for manufacturability evaluation, 
formulation optimization, analytical method development and determination of product 
shelf-life. [298] Degradation studies have also provided an integral framework for the 
assessment of biosimilarity in regulatory filings [96,150,151,194,301], since these stress 
conditions highlight subtle structural differences that may not be readily detected without 
forced degradation. [318] The results of forced degradation studies may vary depending 
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on the stress condition and type of mAbs being evaluated on top of the inherent 
differences between the originator (OR) and biosimilar (BS). For example, both infliximab 
OR and BS showed significant formation of high molecular weight forms, resulting in 
reduced TNF-α binding, when stressed at pH 2.9 under 5ºC for 8 days, while increased 
deamidation, resulting from thermal stress at 45 ºC for 10 days, had no impact on TNF-α 
binding. [150] In addition, rituximab OR and BS showed different rates of aggregate 
formation after 15 days of incubation at 50 ºC. [66]  
In this study, we used three different innovator and biosimilar pairs; rituximab, 
bevacizumab, and trastuzumab. Our objective was to determine which methods are best 
suited for detecting initial structural differences between the OR and BS. We 
subsequently investigated how these differences changed over the course of 4 weeks of 
incubation at 40ºC, with orbital shaking at 250 RPM, by comprehensive structural analysis 
using an array of highly sensitive chromatographic and biophysical assays. 
 Materials and methods 
4.3.1 Samples and reagent 
All drugs were purchased and stored at 4ºC until use (Rituxan®, Avastin®, 
Herceptin® (Genetech), Acellbia®, HERtiCAD®, Avegra® (Biocad)). Bacteriostatic 0.9% 
sodium chloride injection, USP was purchased from Pfizer Inc. (New York City, NY, US) 
All MS grade reagents were from Fisher Scientific (Hampton, NH, US). The chemicals 
were purchased from Sigma-Aldrich (Milwaukee, WI, US). 
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4.3.2 Sample incubation 
Samples were diluted to 1 mg/mL using 0.9% bacteriostatic sodium chloride 
injection, USP. Samples were incubated at 40 ºC with 250 RPM orbital shaking for 4 
weeks.  
4.3.3 Circular dichroism 
CD was carried out using Jasco J-815 CD spectrometer equipped with 
temperature controller (CDF-426S/15) and Peltier cell (Jasco, Oklahoma City, OK) at 25 
°C. CD data were collected from 190 to 260 nm with scanning speed of 50 nm/min, band 
width of 1nm and a DIT of 1 sec using Spectrosil® far UV quartz cells with 1 mm 
pathlength. CDPro analysis (CONTIN) was used for analyzing CD spectra to determine 
the secondary structure contents. CD data were plotted after being converted to mean 
residual ellipticity (MRE) using the following equation.  
[θ]mrw, λ = MRW X
θλ
10 𝑋 𝑑 𝑋 𝑐
 
θλ: observed ellipticity in degrees at wavelength λ 
d: path length (cm)  
c: concentration (g/mL) 
4.3.4 Intrinsic fluorescence 
Intrinsic fluorescence of antibody samples (1 mg/mL) was measured in ultra-micro 
cell black quartz cuvettes (1.5 x 1.5 mm optical path length) (Hellma, Müllheim, Germany) 
using a SpectraMax3 (Molecular devices, San Jose, CA) with excitation at 280 nm and 
emission ranging from 280 nm to 450 nm.  
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4.3.5 Ion mobility mass spectrometry and collision induced unfolding 
All antibody samples, native and thermally stressed, were buffer exchanged into 
200 mM ammonium acetate buffer using Micro Bio-spin 30 columns (Bio-Rad, Hercules, 
CA). Buffer exchanged samples were then diluted to a working concentration of 1 mg/mL 
(~6.7 µM).  
Antibody samples were analyzed using a quadrupole-ion mobility-time-of-flight 
mass spectrometer (Q-IM-ToF MS) instrument (Synapt G2 HDMS, Waters, Milford, MA). 
Sample was transferred to a gold-coated borosilicate capillary needle (prepared in-
house), and ions were generated by direct infusion using a nano-electrospray ionization 
(nESI) source in positive mode. The electrospray capillary was operated at voltages of 
1.5-1.7 kV with the sampling cone operated at 40 V. The backing pressure was set to 
~7.9-8.1 mbar. The helium cell flow was operated at 200 mL/min and pressurize to 
1.40x103 mbar. The trap traveling-wave ion guide was pressurized to 4.93 × 10−2 mbar 
with argon gas. The traveling- wave IM separator was operated at a pressure of ∼3.4 
mbar. IM separation was achieved with a travelling wave operated at 40 V wave height 
traveling at 600 m/s. The ToF-MS was operated over the m/z range of 100−10,000 at a 
pressure of 1.5 × 10−6 mbar. 
Antibody ions were subjected to collisions in the travelling-wave ion trap prior to 
the IM separation to perform all charge state antibody CIU. The collision voltage was 
ramped from 5 to 200 V in 5 V increments to construct the CIU fingerprint data. The dwell 
time for each 5 V step was 6 seconds. Drift time data was extracted at each collision 
voltage in DriftScope (Waters, Milford, MA) using TWIMExtract. [349] These extracted 
drift time data were analyzed using a home-built software package, CIUSuite 2. [350] 
 99 
4.3.6 Intact mass spectrometry 
Each antibody sample was buffer-exchanged 4 times into a 20% acetonitrile 
solution containing 1% acetic acid using a 10 KDa Amicon® Ultra filter (EMD Millipore, 
Burlington, MA). Antibody was recovered from the filter unit in water and concentration 
was measured by a Qubit fluorometer (Invitrogen, Carlsbad, CA). Sample concentration 
was reduced to 0.5 mg/mL with LC-MS grade water. Samples were separated and 
analyzed by a C4 column (X-Bridge BEH C4 2.1 x 50 mm) (Waters, Milford, MA) 
interfaced to a Q Exactive mass spectrometer (ThermoFisher, Waltham, MA). Data were 
acquired from 600-4000 m/z at a resolution of 17,500 FWHM (at 400 m/z) with 10 μscans 
per spectrum (intact mass). Spectral deconvolution and analysis were performed using 
Intact Mass™ ver 3.3 (Protein Metrics Inc., San Carlos, CA). 
4.3.7 Cation exchange chromatography  
CEX was performed on an Alliance HPLC (Waters, Milford, MA) equipped with 
PDA detector. Antibody samples were centrifuged for 10 min at 15,000 RPM and injected 
(30 µL) onto a MAbPac SCX-10 column (4 x 150 mm, 5 µm) (Thermofisher, Waltham, 
MA). Mobile phase A was 20 mM MES buffer (pH 5.6) and mobile phase B was 20 mM 
MES buffer with 300 mM NaCl (pH 5.6). The flow rate was 1 mL/min at 30°C for 20 min 
using a linear 30-60% B gradient. The signal was detected at 280 nm.  
4.3.8 Size exclusion chromatography 
Antibody samples were centrifuged for 10 min at 15,000 RPM. Samples (25 µL) 
were injected into a Waters Alliance HPLC system and separated with a TSKgel 
SuperSW mAb HR column (7.8 mm x 30.0 cm, 4 µm, 25 nm) (Tosoh, Tokyo, Japan). 0.2 
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M phosphate buffer (pH 6.7) with 0.05% NaN3 was used for the mobile phase with a flow 
rate of 0.8 mL/min. The signal was detected at 280 nm. 
4.3.9 SDS-PAGE 
SDS-PAGE was performed under reducing and non-reducing conditions in pre-
cast NuPAGE® 3-8% tris-acetate gel (Invitrogen, Carlsbad, CA). Antibody samples (7.5 
µg) were mixed with NuPAGE® LDS sample buffer (Invitrogen, Carlsbad, CA) to make a 
final volume of 10 µL. For reducing SDS PAGE, 1 µl of NuPAGE® reducing agent was 
added. Samples were heat denatured at 70 °C for 10 minutes. HiMark prestained protein 
standard (Invitrogen, Carlsbad, CA) was used for the protein ladder. For reducing SDS 
PAGE, 0.5 ml of antioxidant was added to the running buffer in the upper chamber. 
Electrophoresis was carried out at a constant voltage of 150 V for 1 hour with XCell 
SureLock Mini-Cell (Invitrogen, Carlsbad, CA). Gels were stained with SimplyBlue Safe 
stain (Thermofisher) and analyzed by Fluorchem M (ProteinSimple, San Jose, CA).  
Table 4-1 Formulation of mAbs. 
 Rituximab Bevacizumab Trastuzumab 
Concentration 10 mg/ml 25 mg/ml 21 mg/ml 
Form Solution Solution Lyophilized powder 
Buffering agent 7.35 mg/ml Sodium citrate 
dihydrate 
5.8 mg/ml Sodium 
phosphate monobasic 
monohydrate 
1.9 mg/ml L-Histidine 
  1.2 mg/ml Sodium 
phosphate dibasic 
anhydrous 
2.4 mg/ml L-Histidine HCl 
Tonicity modifier 9 mg/ml Sodium chloride   
Lyo-protector 60 mg/ml α, α-trehalose 
dihydrate 
 19.1 mg/ml α, α-trehalose 
dihydrate 
surfactant 0.7 mg/ml Polysorbate 80 1.6 mg/ml Polysorbate 20 0.09 mg/ml Polysorbate 20 
pH 6.5 6.2 6 
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 Results  
4.4.1 Initial structural differences between the originator and the biosimilar 
First, we performed far UV circular dichroism (CD) (190-260 nm) and intrinsic 
fluorescence (IF) to detect differences of secondary and tertiary structure. Circular 
dichroism detects secondary structure of proteins by measuring absorbance differences 
of left and right circularly polarized light. [74] Intrinsic fluorescence measures the 
conformational changes of proteins derived from the fluorescence of aromatic amino 
acids, which are sensitive to local environment changes. [386] CD spectra for three mAb 
pairs were shown in Figure 4-1 a-c and were well overlapped between OR and BS. Also, 
the resulting structural contents (α-helix, β-sheet, β-turn, and random coil) were highly 
similar between OR and BS with their secondary structure being mainly composed of β-
sheet, turns and random coil (Table 1). In addition, IF spectra for the three mAb pairs are 
shown in Figure 4-1 d-f. IF spectra were well-overlapped for each mAb pair. The emission 
wavelength of maximum intensity for the rituximab pair was found to be 335 nm, while the 
emission wavelength of maximum intensity for bevacizumab and trastuzumab pairs was 
found to be 340 nm. Altogether, there were no significant secondary or tertiary structural 
differences detected by CD and IF between OR and BS. 
Next, we utilized ion mobility mass spectrometry (IM-MS), which has previously 
been implemented in biosimilar comparison studies by detecting subtle differences in 
features such as glycosylation and disulfide bonds [53,56,318], for the characterization of 




Figure 4-1 Representative far UV circular dichroism spectra of (a) rituximab pair, (b) 
bevacizumab pair and (c) trastuzumab pair. Representative intrinsic fluorescence spectra of (d) 
the rituximab pair, (e) the bevacizumab pair and (f) the trastuzumab pair. 
 
calculating the CIU50 (the voltage at which 50% of a relatively compact state of the protein 
transitions to an unfolded state), we are able to compare the stability for all transitions 
across different CIU fingerprints. [350] The 24+ charge states were used to generate CIU 
plots, providing suitable transition numbers between features with high confidence. The 
resulting CIU plots are shown in Figure 4-2. We observed 1 stable and 2 unfolded states 
for all 3 OR-BS pairs. Also, we did not detect any significant differences in the stability of 
mAb structure between OR and BS based on the collision energy required to unfold the 
antibody, with the exception of the rituximab pair at the second transition (Figure 4-2d).     
 103 
 
Figure 4-2 Representative CIU fingerprints of (a) the rituximab pair (b) the bevacizumab 
pair and (c) the trastuzumab pair and CIU50 values of (d) the rituximab pair (e) the bevacizumab 
pair and (f) the trastuzumab pair. (N = 3; mean ± SD, Student’s t-test, ****p<0.0001) 
 
Then, a molecular weight (MW) of each antibody was measured by intact mass 
analysis. By comparing observed mass with a protein’s expected mass (based on amino 
acid sequence), information on each antibody’s glycoform profile and PTMs can be 
obtained. The deconvoluted MS spectra of each mAb pair are shown in Figure 4-3 as a 
mirror plot. The presence of various glycoforms and C-terminal Lys species were 
assigned based on deconvoluted MS values. Each mAb showed multiple MW peaks, 
 104 
corresponding to mAb molecules with different N-linked glycoforms and different amounts 
of C-terminal lysine residues (a mass difference of ~162 corresponds to galactose and 
N-acetylglucosamine, ~291: sialic acid, ~146: fucose, and ~128: C-terminal Lys). We 
detected initial MW distribution differences between OR and BS. In general, more MW 
peaks were detected for BS samples, including split peaks shown in rituximab and 
trastuzumab BS samples.  
The rituximab OR contained four of the most abundant glycoforms (G0F/G1F, 
G0F/G2F or (G1F)2, (G0F)2 and G1F/G2F) along with a series of less abundant 
glycoforms. The rituximab BS possessed similar glycoforms, but split peaks were 
detected with MW corresponding to the presence of C-terminal Lys immediately to the 
left of its respective glycoform. There were no new glycoforms detected between the OR 
and BS. The bevacizumab OR showed a simple MW distribution with four glycoforms: 
((G0F)2, G0F/G1F G0F/G2F or (G1F)2 and G1F/G2F). In contrast, the bevacizumab BS 
showed more MW peaks than the OR, with differences derived from the presence of 1 or 
2 C-terminal Lys with similar major glycoforms. Glycoforms containing sialic acid were not 
observed in both the OR and the BS. The trastuzumab OR and BS showed similar major 
glycoforms (G0F/G1F, (G1F)2 or G0F/G2F, (G0F)2, G1F/G2F, G0/G0F, and (G2F)2), but 
showed differences of minor glycoforms. For example, (Man5)2 and (G2F)2 glycoforms 
were only detected in the OR. Differences between the OR and the BS were detected as 





Figure 4-3 Comparison of deconvoluted mass spectra with annotated glycoforms and C-
terminal Lys of (a) the rituximab pair, (b) the bevacizumab pair and (c) the trastuzumab pair. 
 
In addition, we profiled charge variants in the three mAb pairs using CEX (Figure 
4-4). Charge variants in mAbs stem from PTMs during manufacturing, such as sialylation 
and C-terminal Lys clipping, as well as degradation during storage, such as deamidation. 
These charge variants are specified as acidic or basic relative to the main species. For 
CEX, acidic variants will elute out earlier than the main species while basic variants will 
elute out later. The main peak was defined as the largest peak observed for the OR of 
each pair. For all 3 mAb pairs, the BS product contained a smaller main peak fraction and 
a larger portion of basic variants compared to the OR. We confirmed that basic variants 
were mainly derived from C-terminal Lys variations by treating mAbs with 
carboxypeptidase B (CPB), an enzyme that selectively cleaves C-terminal Lys. Overall, 
the CEX data aligned well with the intact mass results and clearly identified differences in 
the number of C-terminal Lys between the OR and BS pairs.  
Lastly, we assessed the presence of mAb aggregates and fragments using SEC. 
SEC is a widely used method to separate protein molecules based on their size in 
solution. [387] The SEC chromatograms are shown in Figure 4-5. The size variants were 
highly similar for each of the 3 mAb pairs, with only the rituximab BS showing a small (2.6 
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± 0.1%) but statistically significant difference in the presence of aggregates compared to 
the OR product. 
 
Figure 4-4 Cation exchange chromatograms and relative percentage peak area of 
charge variants of (a) the rituximab pair, (b) the bevacizumab pair and (c) the trastuzumab pair 






Figure 4-5 Representative SEC chromatograms and relative percentage main peak area 
of for (a) the rituximab pair, (b) the bevacizumab pair and (c) the trastuzumab pair. (N = 3; mean 
± SD, Student’s t-test, ****p<0.0001) 
 
Altogether, our initial structural characterization of the 3 mAb pairs revealed a high 
degree of similarity with minor differences in unfolding and aggregation pattern (the 
rituximab pair) as well as differences in glycoform distribution and charge profiles (all 
pairs). In order to amplify these initial differences between the OR and BS products, we 
subjected each mAb to a 4-week incubation at 40 ºC with orbital shaking.  
4.4.2 Assessment of structural differences after stress 
Over the course of incubation, no structural changes were detected via CD and IF. 
The CD spectra were nearly identical between each OR and BS pair before and during 
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stress, indicating that the secondary structure remained unchanged during incubation. 
The IF spectra were also identical for each mAb pair regardless of incubation time point, 
indicating a high degree of similarity in protein-folding state. (Figure 4-9 and Table 4-2)  
Regarding IM-MS, there were a number of subtle, but statistically significant 
changes after the 4-week incubation. The rituximab OR showed a decreased CIU50-2 
value at week 4, corresponding to a minor destabilization, whereas there were no 
significant difference in the resulting CIU50 values between the stressed OR and BS 
indicating the presence of a terminal CIU50 value for stressed rituximab (Figure 4-9b). 
With the bevacizumab pair, the BS had a higher CIU50-2 (7% difference) than the OR, 
but still within standard deviation of the unstressed BS, suggesting the BS is more stable 
than the OR (Figure 4-9d). The trastuzumab OR showed a higher CIU50-1 than the BS 
after incubation, and both the OR and BS showed similar increases (approximately 2%) 
in CIU50-2 (Figure 4-9f), indicative of a small and unexpected increase in stability of both 
mAbs after incubation that may be related to variance in secondary structure as a result 
of incubation as indicated by the CD data for transtuzumab.   
The post-stress intact MS data for the rituximab and trastuzumab pairs were 
identical to the data obtained from the unstressed samples (Figure 4-3a and c and Figure 
4-10a and c). In short, each OR-BS pair possessed similar major glycoforms, with minor 
differences manifesting as split peaks that correspond to different numbers of C-terminal 
lysines. However, for the bevacizumab pair, we detected the cleavage of N-
acetylglucosamine from the G0F glycan as well as cleavage of the entire G0F glycan from 
the bevacizumab OR upon incubation (Figure 4-3b). 
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The CEX profiles of all 6 mAbs showed a decrease in main peak area and 
increases in a combination of acidic and basic-peak areas over the course of the 4-week 
stress period (Figure 4-6). In general, the largest changes in charge variant distribution 
occurred in the 3 OR products. The main peak areas for the Rituximab, Bevacizumab, 
and Trastuzumab OR products decreased by 14%, 11%, and 29%, respectively. In 
contrast, the main-peak areas of the 3 BS products decreased by 5%, 1%, and 19%, 
respectively. Interestingly, the trastuzumab pair showed the most changes during the 
incubation, with both the OR and BS products having statistically significant differences 
in acidic, main, and basic-peak areas when comparing unstressed to 4-week stressed 
samples (Figure 4-6h and i). As with the unstressed samples, we confirmed that basic 
variants in all 3 pairs were derived from C-terminal Lys variations by treating mAbs with 
carboxypeptidase B (CPB), an enzyme that selectively cleaves C-terminal Lys.  
Across all 3 mAb pairs, the incubation period brought about no significant changes 
in the levels of aggregates and fragments based on SEC data. The initial differences 
between each OR-BS pair in terms of aggregation and fragmentation accounted for any 
differences observed over the course of the incubation (Figure 4-7a and b). To confirm 
the SEC results, we also performed reducing and non-reducing SDS-PAGE as an 
orthogonal method (Figure 4-7c). In general, the data from SDS-PAGE supported the 
observations made by SEC. SDS-PAGE data were corresponded well to SEC data where 
the presence of dimer for the rituximab BS and bevacizumab pair. In addition to monomer 
mAb bands, smaller molecular weight bands (approximately 100 kDa : 2 heavy chain and 
125 kDa: 2 heavy chains and 1 light chain) were also observed under non-reducing 




Figure 4-6  Representative CEX chromatograms of (a) the rituximab pair, (d) the 
bevacizumab pair and (g) the trastuzumab pair. The calculated percentage area of acidic, main 
and basic peaks of (b, c) the rituximab pair (e, f) the bevacizumab pair and (h, i) the 




Figure 4-7 Representative SEC chromatograms and the calculated percentage of main 
peak of (a) the rituximab pair, (b) bevacizumab pair and (c) trastuzumab pair. (N = 3; mean ± 
SD, Student’s t-test, *p<0.05, **p<0.01, ****p<0.0001) 
 
significant difference was detected for each band over the course of incubation. Two 
distinct bands were detected under reducing conditions, corresponding to heavy and light 
chain. Only the bevacizumab pair showed faint bands around 41 KDa, which indicates a 






Figure 4-8 Non-reducing SDS-PAGE gel of (a) the rituximab pair, (b) the bevacizumab 
pair and (c) the trastuzumab pair and reducing SDS-PAGE gel of (d) the rituximab pair, (e) the 
bevacizumab pair and (f) the trastuzumab pair at 0,2 and 4 weeks thermal stress. HC: heavy 
chain, LC: light chain  
 
 Discussion 
In this study, forced degradation was used to compare the biosimilarity of OR and 
BS pairs in terms of the presence of initial structural differences and how those aspects 
change when subject to thermal stress. Three different pairs, including rituximab, 
bevacizumab and trastuzumab, were used for the entire analysis. Although each pair of 
drug products were manufactured with identical cell lines (Chinese Hamster Ovary cells) 
and formulations [391], they were still subjected to the inherent variability of 
manufacturing processes. All samples were diluted to 1 mg/ml with 0.9% NaCl, the 
appropriate condition for intravenous infusion when administered. [384,392,393] Then, 
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structural analyses were performed with various techniques to identify and track how 
initial differences between the OR and BS pairs changed upon incubation  
Our study revealed that both the OR and BS for all drug products are structurally 
stable after 4 weeks of thermal stress. No differences in terms of secondary and tertiary 
structures measured by CD and IF were detectable over the course of incubation. This 
reflects how structurally stable mAbs are below their melting temperature. Previous 
studies have demonstrated that thermal unfolding of antibodies occurs over 55 ºC, with 
CD spectra shapes changing when incubated above this temperature [394–396]. In 
addition, a recent study subjecting Remicade and Remsima to both high humidity and 
thermal stress at 40ºC showed highly similar secondary structure data by CD over the 
entire course of incubation. However, unlike our result, a decrease in maximum 
fluorescence intensity was observed with high homology between two products by IF 
[318].  
Aggregation and fragmentation were measured by SEC. The AUC of the monomer 
peak remained similar over the course of incubation, with a rate of monomer loss 
measured within 1 % for all three pairs for 4 weeks. No significant increases in 
aggregation levels were detected by SEC and SDS-PAGE. The trastuzumab pairs 
showed the lowest levels of initial aggregation, which is likely attributed to the fact that, 
as opposed to the other mAb pairs which are already in solution, trastuzumab is a 
lyophilized product that is mixed with water prior to injection. Interestingly, the relative 
levels of aggregation and fragmentation remained similar over the course of incubation, 
reflecting the ability of the formulation to prevent aggregation for each mAb pair even 
when diluted (Rituximab contains polysorbate 80 while bevacizumab and trastuzumab 
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contain polysorbate 20.) Buffer systems without surfactant have been used as another 
stress condition to truly test if the formulation was responsible for the prevention of 
aggregate formation. [397–400] However, it should be noted that buffers without 
surfactant differ from a real-world situation. A recent briefing document for FDA biosimilar 
approval indicated that Remicade and Remsima showed comparable levels of the 
monomer peak with no discernable changes detected when incubated (containing 
polysorbate 80) at 40ºC for 3 months. [96] In addition, a long-term stability study of diluted 
rituximab at 40ºC was performed for 6 months, where similar levels of aggregates, 
increased fragmentation and unchanged structural contents were reported, which aligns 
with our results. [401]  In general, SDS-PAGE showed better resolution than SEC 
regarding the detection of fragments; SEC chromatograms only showed one fragment 
peak, whereas SDS-PAGE showed 5 fragment peaks including 2HC+1LC, 2HC and 1HC. 
CIU-IM-MS analysis provided a gas phase folding stability profile for the OR and 
BS pairs both before and after incubation. The trastuzumab pair showed the most notable 
change in unfolding via different CIU50 values when comparing unstressed and 4-week 
stressed. Again, this may be attributed to trastuzumab’s lyophilized formulation, unlike 
the other mAb pairs that are shipped as liquid formulations. Based on our results, the 
CIU50 approach is capable of monitoring subtle changes in mAbs between the OR and 
BS pairs as well as between stressed and unstressed mAbs. Recently, Kerr et. al used 
CIU-IM-MS data to compare the structural stability of originators rituximab, bevacizumab 
and trastuzumab when subject to incubation at 25 ± 2ºC for 6 months. In this study, 
bevacizumab showed the most differences in unfolding after incubation, indicated by the 
presence of an additional transition in the CIU plots. [402] This difference from our findings 
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can be attributed to the different methods used to quantify changes in structural stability 
– Kerr et al based structural stability on the 25+ charge state and a scaled deviation score 
value that was further supported by root-mean-squared deviation (RMSD), while our data 
is based on the 24+ charge state CIU50 following sigmoidal fitting. The CIU value is 
relatively independent of signal intensity and, in some cases, provides a better diagnostic 
for comparing stability shifts in samples, whereas RMSD tells us information about where 
those differences are most intense in the CIU. [350] 
CEX analysis showed the most initial differences between the OR and BS pairs, 
which included an especially high level of basic variants in all three BS drugs. The basic 
variants, typically characterized by differences in C-terminal lys presence, tends to be 
benign in terms of their effect on mAb safety or efficacy. [190] However, deamidation of 
asparagine residues located on the CDR regions can reduce antigen binding affinity . 
[318,403–405] Further fraction collection and follow-up MS analysis is needed to identify 
the exact deamidation site of each acidic peak variant. Interestingly, the CEX peak 
identities became less distinctive over the course of incubation while area under the curve 
remained similar (RSD less than 5%). A similar tendency was also observed in a previous 
study when IgG1 subjects to thermal stress at 25 ºC for 12 months with mild chemical 
oxidation by tBHP. CEX peaks became indistinctive due to the formation of a basic 
shoulder derived from methionine sulfoxide that retains longer on the CEX column. [406] 
In addition, an increase of acidic variants was commonly observed upon thermal stress 
[186,403,407–410] where the OR and BS also showed an increased level of acidic 
variants upon incubation.  
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Intact MS analysis showed initial difference between the OR and BS regarding the 
global mAb structure. While intact MS can provide a fast analysis of the major glycoforms 
and some PTMs, such as C-terminal lysine, it is hard to assign other chemical 
modifications with small mass differences such as deamidation (+1) and oxidation (+16) 
by intact MS. [163] Overall, glycans were well matched between the OR and BS. A 
difference in peak numbers, derived from different numbers of C-terminal lysine which 
were also well corresponded to CEX data, showed distinctive basic charge variant peaks 
that OR drugs did not contain.  
Taken together, our research highlights the comparison of higher order structure 
and charge variants between the OR and the BS when subject to thermal stress 
conditions. Because of the highly similar properties between the OR and the BS, their 
behaviors were similar when subject to thermal incubation. We demonstrated the 
capability of CIU-IM-MS to detect subtle differences between the OR and the BS. Future 
studies are needed to identify changes of individual amino acid modifications and their 





Figure 4-9 Representative far UV circular dichroism spectra of (a) the rituximab pair, (b) 
the bevacizumab pair and (c) the trastuzumab pair at 0 and 4 weeks. Representative intrinsic 
fluorescence spectra of (d) the rituximab pair, (e) the bevacizumab pair and (f) the trastuzumab 




Figure 4-10 Representative CIU fingerprints of (a) the rituximab pair (c) the 
bevacizumab pair and (e) the trastuzumab pair and CIU50 values of (b) the rituximab pair (d) 
the bevacizumab pair and (f) the trastuzumab pair at 0 and 4 weeks. (N = 3; mean ± SD, 
Student’s t-test, *p<0.05, ***p<0.001, ****p<0.0001) 
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Table 4-2 Secondary structure composition of the rituximab, bevacizumab and 
trastuzumab pairs over the course of incubation at 40ºC. 
Sample Incubation α-helix β-sheet β-turn Random coil 
Rituximab 
OR 
0wk 2.3 ± 0.6 45.2 ± 2.1 20.2 ± 0.5 32.3 ± 1.1 
2wk 2.5 ± 0.3 45.1 ± 0.9 20.2 ± 0.2 32.3 ± 0.4 
4wk 2.7 ± 0.2 45.1 ± 1.4 20.1 ± 0.4 32.1 ± 1.0 
BS 
0wk 2.2 ± 0.5 45.4 ± 1.7 20.2 ± 0.4 32.2 ± 0.4 
2wk 1.9 ± 0.6 45.7 ± 1.9 19.8 ± 0.6 32.6 ± 1.4 
4wk 2.5 ± 0.2 44.6 ± 0.2 20.3 ± 0.1 32.5 ± 0.3 
Bevacizumab 
OR 
0wk 2.6 ± 0.2 43.5 ± 0.4 20.2 ± 0.1 33.7 ± 0.3 
2wk 2.4 ± 0.4 43.9 ± 1.6 20 ± 0.4 33.8 ± 0.8 
4wk 2.5 ± 0.1 43.5 ± 0.1 20.3 ± 0.1 33.7 ±0.1 
BS 
0wk 2.4 ± 0.1 43.6 ± 0.1 20.2 ± 0.1 33.8 ± 0.1 
2wk 2.5 ± 0.2 43.5 ± 1.0 20.3 ± 0.4 33.7 ± 0.1 
4wk 2.2 ± 0.2 44.6 ± 0.3 19.9 ± 0.4 33.3 ± 0.3 
Trastuzumab 
OR 
0wk 2.4 ± 0.2 44.9 ± 1.3 20.3 ±  0.4 32.3 ± 0.8 
2wk 2.5 ± 0.3 45.6 ± 0.9 20.1 ± 0.3 31.8 ± 0.6 
4wk 3.1 ± 0.5 42.8 ± 2.2 20.6 ± 0.5 33.5 ± 1.2 
BS 
0wk 2.9 ± 0.1 43.2 ± 0.6 20.8 ± 0.3 33.1 ± 0.4 
2wk 3.0 ± 0.2 42.8 ± 1.1 21.0 ± 0.3 33.3 ±  0.7 
4wk 2.9 ± 0.1 43.4 ± 0.2 20.9 ± 0.1 32.8 ± 0.1 
 
 
Figure S 4-1 Comparison of deconvoluted mass spectra with annotated glycoforms and C-
terminal Lys of (a) rituximab pair, (b) bevacizumab pair and (c) trastuzumab pair at 4-week 
thermal stress. 
Figure 4-11 Comparis n of deconvoluted ma s spectra with annotated glycoforms and 
C-terminal Lys of (a) the rituximab pair, (b) the bevacizumab pair and (c) the trastuzumab pair at 
4-week thermal stress. 
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Chapter 5: Conclusions and Prospective 
The work presented in this thesis compares originator (innovator) and biosimilar 
biologics using various analytical techniques to validate biosimilarity. The utility of state-
of-the-art-techniques, orthogonal methods and stressed conditions provide valuable data 
on how to test for biosimilarity regarding the structural and functional aspects of these 
biologic molecules.  
The use of biosimilars provide a great option for patients by increasing their access 
to life-saving treatments at lower costs. In chapter 2, we focused on structural comparison 
between the originator and the biosimilar filgrastim which had a relatively simple structure 
and small numbers of PTMs relative to those found in our studied mAb drugs. We 
observed identical primary structures and very similar higher order structures. While 
previous studies from other biosimilar developers have reported analytical comparability 
between the originator and biosimilar using various analytical techniques, we were the 
first to show its comparative unfolding pattern by IM-MS. The 2D-NMR analysis performed 
to compare biosimilar filgrastim to the originator Neupogen had been submitted to the US 
FDA to prove the structural similarity of these two products which implications that allowed 
the company to avoid performing a costly clinical comparability study. The similarity 
between the oxidation levels at Met residues located in close proximity to the G-CSF 
receptor binding sites have been used to infer similar biological activity between the 
originator and biosimilar. However, investigating the actual similarity for target binding 
between the two products could further confirm their similarity.   
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In chapter 3, we analyzed the structural comparability between originator and a 
biosimilar rituximab a specific focus on glycosylation differences and their impact on 
biological activity. Both showed almost identical primary and higher order structures with 
minor differences in PTM levels, which include pyroGlu formation, C-terminal Lys clipping 
and glycoform distributions. A study by our laboratory has shown that afucosylation 
differences between the originator and the biosimilar can result in different FcγIIIa 
receptor binding affinities, potentially resulting in differences in clinical efficacy of the two 
products. This is especially important for drugs like rituximab that treat diseases which 
are Fc-mediated efficacy like IBD and cancer. [53,376]  Based on this observation, 
rituximab was chosen as a model drug to correlate afucosylation levels with the drug’s 
biological activity - ADCC. The biosimilar showed higher afucosylation levels which 
manifested into both a higher FcγIIIa receptor binding affinity and ADCC activity. 
Importantly, we saw different detection sensitivities for glycoform distributions which were 
highly analytical method dependent, which further underlines the value of the use of 
orthogonal analytical techniques and the high glycoform resolving power of LC-MS/MS 
methodology. In addition, MAM was proven to provide extensive data on several quality 
attributes such as the primary sequence, amino acid modification and glycan distribution 
by a single method. These MAM approaches will be a crucial part of biosimilar 
development.  
Finally, we showed several initial structural differences and similarities present in 
the three different mAb originator-biosimilar pairs and then compared them after exposure 
to thermal stress conditions, which can be found in Chapter 4. The idea was that subtle 
initial differences present between the originator and biosimilar could be amplified when 
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the proteins are subjected to forced degradation conditions, while their behaviors in 
response to the stress conditions would be similar. The most distinct differences between 
the originators and the biosimilars are detected in major glycoform and charge variant 
distributions that are commonly defined by the manufacturing process. After applying 
thermal stress, we saw differences in unfolding patterns by CIU-IM-MS that were 
seemingly derived from the difference in initial dosage forms, one as a solution and the 
other a lyophilized cake. Additional studies on the biological activity of each mAb after 
thermal stress would provide valuable data on confirming true stability and biosimilarity. 
Additional experiments to assess PTMs at the amino acid level are also necessary in 
order to understand the source of charge variants. While the work presented in Chapter 
4 is mainly related to higher order structures, it presents a non-traditional way of 
demonstrating biosimilarity.  
The main concerns regarding biosimilars that have been raised are differences of 
immunogenicity and efficacy between an originator and a biosimilar in certain specific 
disease indications. These two aspects of innovator and biosimilar differences are 
especially importiant clinically when considering biosimilar interchangeability. If the 
biosimilar is designated as interchangeable, the switch of prescription from an originator 
to a biosimilar (or vice versa) could be performed by a pharmacist without the knowledge 
of either the patient or physician. While there are currently no interchangeable biosimilars 
approved in US, the FDA has recently released its final guidance for the demonstration 
of biosimilar interchangeability. [411] Boehringer Ingelheim has started a switching study 
with the intent for its adalimumab biosimilar to be designated as interchangeable. Recent 
studies comparing the infliximab originator and two biosimilars revealed variation in 
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afucosylation levels, which resulted in a significant difference in the relative FcγRIIIa 
receptor binding affinity while following a similar trend for ADCC. [53,328]  The results of 
the NOR-SWITCH study on switching from originator to biosimilar treatment showed that 
the biosimilar showed the rate difference of -14.4% with Crohn’s disease patients (close 
to the pre-defined 15% non-inferiority margin). [412] This result has raised a question 
about whether the biosimilar is less effective in Crohn’s disease. In this regard, our 
research investigating the differences in afucosylation and ADCC between an originator 
and a biosimilar could provide insights for acceptable specifications for interchangable 
biosimilar products. By establishing specifications around afucosylation levels, the 
differences in patient responses upon switching could be minimized. Thus, future studies 
need to be completed to establish how much afucosylation and ADCC variation is 
necessary to be considered clinically meaningful. Auxiliary to glycan differences, an allelic 
V-F polymorphism in FCGR3 gene at residue 158 result in individual patient’s different 
response to mAb treatment (V/V – strong response). [413] Therefore, understanding the 
collective impact of glycosylation differences and genetic polymorphism on treatment 
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